{"relationship_key":"prov:96d5f09b7d8c44d7b33404f9be7d5fa1:associated_with:prov:e51e2693aaf2469fabf45c7eeb013046","document_id":"PMC12757429_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"Our findings demonstrate that PSMD14 acts as a key driver of LUAD progression","confidence":0.7,"supports":true}
{"relationship_key":"prov:96d5f09b7d8c44d7b33404f9be7d5fa1:associated_with:prov:e51e2693aaf2469fabf45c7eeb013046","document_id":"PMC12757429_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"Our findings demonstrate that PSMD14 acts as a key driver of LUAD progression","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Ubiquitin:associated_with:prov:e51e2693aaf2469fabf45c7eeb013046","document_id":"PMC12757429_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"Ubiquitination, an essential post-translational modification, orchestrates diverse cellular processes such as proliferation, apoptosis, migration, drug resistance, and tumor development","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Ubiquitin:associated_with:prov:e51e2693aaf2469fabf45c7eeb013046","document_id":"PMC12757429_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"Ubiquitination, an essential post-translational modification, orchestrates diverse cellular processes such as proliferation, apoptosis, migration, drug resistance, and tumor development","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Ubiquitin:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"Ubiquitination, an essential post-translational modification, orchestrates diverse cellular processes such as proliferation, apoptosis, migration, drug resistance, and tumor development","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Ubiquitin:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"Ubiquitination, an essential post-translational modification, orchestrates diverse cellular processes such as proliferation, apoptosis, migration, drug resistance, and tumor development","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Apoptosis:associated_with:prov:e51e2693aaf2469fabf45c7eeb013046","document_id":"PMC12757429_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"Ubiquitination, an essential post-translational modification, orchestrates diverse cellular processes such as proliferation, apoptosis, migration, drug resistance, and tumor development","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Apoptosis:associated_with:prov:e51e2693aaf2469fabf45c7eeb013046","document_id":"PMC12757429_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"Ubiquitination, an essential post-translational modification, orchestrates diverse cellular processes such as proliferation, apoptosis, migration, drug resistance, and tumor development","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Apoptosis:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"Ubiquitination, an essential post-translational modification, orchestrates diverse cellular processes such as proliferation, apoptosis, migration, drug resistance, and tumor development","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Apoptosis:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"Ubiquitination, an essential post-translational modification, orchestrates diverse cellular processes such as proliferation, apoptosis, migration, drug resistance, and tumor development","confidence":0.7,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:associated_with:UniProt:Q9NDE7","document_id":"PMC12757429_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"HBE135-E6E7 cells were grown in Keratinocyte Serum-Free Medium (Zhong Qiao Xin Zhou Biotechnology, Shanghai, China) supplemented with 0.005 mg/mL insulin","confidence":0.8,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:associated_with:UniProt:Q9NDE7","document_id":"PMC12757429_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"HBE135-E6E7 cells were grown in Keratinocyte Serum-Free Medium (Zhong Qiao Xin Zhou Biotechnology, Shanghai, China) supplemented with 0.005 mg/mL insulin","confidence":0.8,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:associated_with:RxNorm:5492","document_id":"PMC12757429_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"HBE135-E6E7 cells were grown in Keratinocyte Serum-Free Medium (Zhong Qiao Xin Zhou Biotechnology, Shanghai, China) supplemented with 0.005 mg/mL insulin, 500 ng/mL hydrocortisone","confidence":0.8,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:associated_with:RxNorm:5492","document_id":"PMC12757429_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"HBE135-E6E7 cells were grown in Keratinocyte Serum-Free Medium (Zhong Qiao Xin Zhou Biotechnology, Shanghai, China) supplemented with 0.005 mg/mL insulin, 500 ng/mL hydrocortisone","confidence":0.8,"supports":true}
{"relationship_key":"prov:442739a1f6bb4fe9ad092f4c7a3bf940:manages:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"HBE135-E6E7 cells were grown in Keratinocyte Serum-Free Medium (Zhong Qiao Xin Zhou Biotechnology, Shanghai, China)","confidence":0.9,"supports":true}
{"relationship_key":"prov:442739a1f6bb4fe9ad092f4c7a3bf940:manages:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"HBE135-E6E7 cells were grown in Keratinocyte Serum-Free Medium (Zhong Qiao Xin Zhou Biotechnology, Shanghai, China)","confidence":0.9,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:associated_with:prov:8bac0d44f0fc4299af923658bfaae42d","document_id":"PMC12757429_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"For the CCK-8 assay, LUAD cells were seeded in 96-well plates at a density of 1 × 10³ cells per well in 100 µL of complete medium and allowed to adhere under standard culture conditions.","confidence":1.0,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:associated_with:prov:8bac0d44f0fc4299af923658bfaae42d","document_id":"PMC12757429_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"For the CCK-8 assay, LUAD cells were seeded in 96-well plates at a density of 1 × 10³ cells per well in 100 µL of complete medium and allowed to adhere under standard culture conditions.","confidence":1.0,"supports":true}
{"relationship_key":"RxNorm:9800:treats:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"For the CCK-8 assay, LUAD cells were seeded in 96-well plates at a density of 1 × 10³ cells per well in 100 µL of complete medium and allowed to adhere under standard culture conditions.","confidence":1.0,"supports":true}
{"relationship_key":"RxNorm:9800:treats:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"For the CCK-8 assay, LUAD cells were seeded in 96-well plates at a density of 1 × 10³ cells per well in 100 µL of complete medium and allowed to adhere under standard culture conditions.","confidence":1.0,"supports":true}
{"relationship_key":"DBPedia:Hoechst_stain:indicates:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_11","section":null,"start_offset":0,"end_offset":0,"text_span":"Finally, cell nuclei were counterstained with Hoechst 33342 for 10 minutes.","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Hoechst_stain:indicates:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_11","section":null,"start_offset":0,"end_offset":0,"text_span":"Finally, cell nuclei were counterstained with Hoechst 33342 for 10 minutes.","confidence":0.9,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:diagnosed_by:DBPedia:Wound_healing_assay","document_id":"PMC12757429_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"For the wound healing assay, LUAD cells were seeded in 6-well plates.","confidence":0.9,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:diagnosed_by:DBPedia:Wound_healing_assay","document_id":"PMC12757429_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"For the wound healing assay, LUAD cells were seeded in 6-well plates.","confidence":0.9,"supports":true}
{"relationship_key":"prov:405e10477c7c466ab804bf1689c03bad:treats:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"The cytotoxicity of Capzimin against LUAD cells was assessed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay","confidence":0.9,"supports":true}
{"relationship_key":"prov:405e10477c7c466ab804bf1689c03bad:treats:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"The cytotoxicity of Capzimin against LUAD cells was assessed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Hoechst_stain:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"cell nuclei were counterstained with Hoechst 33342 for 10 minutes","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Hoechst_stain:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"cell nuclei were counterstained with Hoechst 33342 for 10 minutes","confidence":0.8,"supports":true}
{"relationship_key":"prov:6b6b4a97f0d344f1bacff74a43f0385d:indicates:DBPedia:Apoptosis","document_id":"PMC12757429_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"Changes in mitochondrial membrane potential (ΔΨm) following PSMD14 inhibition were assessed by flow cytometry using the JC-1 fluorescent probe","confidence":0.6,"supports":true}
{"relationship_key":"prov:6b6b4a97f0d344f1bacff74a43f0385d:indicates:DBPedia:Apoptosis","document_id":"PMC12757429_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"Changes in mitochondrial membrane potential (ΔΨm) following PSMD14 inhibition were assessed by flow cytometry using the JC-1 fluorescent probe","confidence":0.6,"supports":true}
{"relationship_key":"prov:32939f1cb5f54fef8e1e651d270f4cd4:located_in:prov:a44435cbadad4e0299d5953b14d4b42b","document_id":"PMC12757429_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"All animal experiments were approved by the Institutional Animal Care and Use Committee of Nanchang Royo Biotech Co., Ltd.","confidence":0.5,"supports":true}
{"relationship_key":"prov:32939f1cb5f54fef8e1e651d270f4cd4:located_in:prov:a44435cbadad4e0299d5953b14d4b42b","document_id":"PMC12757429_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"All animal experiments were approved by the Institutional Animal Care and Use Committee of Nanchang Royo Biotech Co., Ltd.","confidence":0.5,"supports":true}
{"relationship_key":"prov:6b6b4a97f0d344f1bacff74a43f0385d:indicates:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_17","section":null,"start_offset":0,"end_offset":0,"text_span":"the JC-1 fluorescent probe (Beyotime, Shanghai, China) was employed to detect changes in ΔΨm","confidence":0.8,"supports":true}
{"relationship_key":"prov:6b6b4a97f0d344f1bacff74a43f0385d:indicates:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_17","section":null,"start_offset":0,"end_offset":0,"text_span":"the JC-1 fluorescent probe (Beyotime, Shanghai, China) was employed to detect changes in ΔΨm","confidence":0.8,"supports":true}
{"relationship_key":"prov:6b6b4a97f0d344f1bacff74a43f0385d:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_17","section":null,"start_offset":0,"end_offset":0,"text_span":"the JC-1 fluorescent probe (Beyotime, Shanghai, China) was employed to detect changes in ΔΨm","confidence":0.8,"supports":true}
{"relationship_key":"prov:6b6b4a97f0d344f1bacff74a43f0385d:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_17","section":null,"start_offset":0,"end_offset":0,"text_span":"the JC-1 fluorescent probe (Beyotime, Shanghai, China) was employed to detect changes in ΔΨm","confidence":0.8,"supports":true}
{"relationship_key":"prov:9c39733346984c1b9e861992edc8e007:contraindicated_for:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"pathway activity scores for EGFR signaling, hypoxia, PI3K, and TNF-a were significantly elevated in the PSMD14 high-expression group","confidence":0.8,"supports":true}
{"relationship_key":"prov:9c39733346984c1b9e861992edc8e007:contraindicated_for:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"pathway activity scores for EGFR signaling, hypoxia, PI3K, and TNF-a were significantly elevated in the PSMD14 high-expression group","confidence":0.8,"supports":true}
{"relationship_key":"prov:9c39733346984c1b9e861992edc8e007:side_effect:MeSH:D004249","document_id":"PMC12757429_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"pathway activity scores for EGFR signaling, hypoxia, PI3K, and TNF-a were significantly elevated in the PSMD14 high-expression group","confidence":0.8,"supports":true}
{"relationship_key":"prov:9c39733346984c1b9e861992edc8e007:side_effect:MeSH:D004249","document_id":"PMC12757429_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"pathway activity scores for EGFR signaling, hypoxia, PI3K, and TNF-a were significantly elevated in the PSMD14 high-expression group","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:A0A481RMQ6:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_26","section":null,"start_offset":0,"end_offset":0,"text_span":"Based on established literature (30), TCGA-LUAD samples were classified into six immune subtypes: C1 (wound healing), C2 (IFN-γ dominant), C3 (inflammatory), C4 (lymphocyte-depleted), C5 (immune silent), and C6 (TGF-β dominant)","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:A0A481RMQ6:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_26","section":null,"start_offset":0,"end_offset":0,"text_span":"Based on established literature (30), TCGA-LUAD samples were classified into six immune subtypes: C1 (wound healing), C2 (IFN-γ dominant), C3 (inflammatory), C4 (lymphocyte-depleted), C5 (immune silent), and C6 (TGF-β dominant)","confidence":0.9,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:diagnosed_by:prov:51d46beed5b44b058b352aa919199ed4","document_id":"PMC12757429_window_27","section":null,"start_offset":0,"end_offset":0,"text_span":"Distribution of six immune subtypes in PSMD14 high- versus low-expression groups (TCGA-LUAD cohort)","confidence":0.9,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:diagnosed_by:prov:51d46beed5b44b058b352aa919199ed4","document_id":"PMC12757429_window_27","section":null,"start_offset":0,"end_offset":0,"text_span":"Distribution of six immune subtypes in PSMD14 high- versus low-expression groups (TCGA-LUAD cohort)","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:A0A481RMQ6:indicates:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_27","section":null,"start_offset":0,"end_offset":0,"text_span":"The C1 (24%) and C2 (51%) subtypes were enriched in the PSMD14 high-expression group, whereas the C3 subtype (61%) was predominant in the low-expression group.","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:A0A481RMQ6:indicates:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_27","section":null,"start_offset":0,"end_offset":0,"text_span":"The C1 (24%) and C2 (51%) subtypes were enriched in the PSMD14 high-expression group, whereas the C3 subtype (61%) was predominant in the low-expression group.","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:DNA_repair:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_27","section":null,"start_offset":0,"end_offset":0,"text_span":"high expression with DNA repair deficiency","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:DNA_repair:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_27","section":null,"start_offset":0,"end_offset":0,"text_span":"high expression with DNA repair deficiency","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Database:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_30","section":null,"start_offset":0,"end_offset":0,"text_span":"To screen for key downstream molecules of PSMD14, we conducted an initial bioinformatic analysis using the GEPIA database","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Database:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_30","section":null,"start_offset":0,"end_offset":0,"text_span":"To screen for key downstream molecules of PSMD14, we conducted an initial bioinformatic analysis using the GEPIA database","confidence":0.7,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:affects:UniProt:Q6PIR6","document_id":"PMC12757429_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"At the protein level, both PSMD14 and HMMR were markedly upregulated in multiple LUAD cell lines compared to normal bronchial epithelial cells (Figure 5A).","confidence":0.9,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:affects:UniProt:Q6PIR6","document_id":"PMC12757429_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"At the protein level, both PSMD14 and HMMR were markedly upregulated in multiple LUAD cell lines compared to normal bronchial epithelial cells (Figure 5A).","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:Q6PIR6:affects:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"At the protein level, both PSMD14 and HMMR were markedly upregulated in multiple LUAD cell lines compared to normal bronchial epithelial cells (Figure 5A).","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:Q6PIR6:affects:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"At the protein level, both PSMD14 and HMMR were markedly upregulated in multiple LUAD cell lines compared to normal bronchial epithelial cells (Figure 5A).","confidence":0.9,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:associated_with:UniProt:Q6PIR6","document_id":"PMC12757429_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"Analysis of TCGA-LUAD data revealed a significant positive correlation between PSMD14 and HMMR expression in clinical specimens (r = 0.56, p < 0.001; Figure 4F).","confidence":0.8,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:associated_with:UniProt:Q6PIR6","document_id":"PMC12757429_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"Analysis of TCGA-LUAD data revealed a significant positive correlation between PSMD14 and HMMR expression in clinical specimens (r = 0.56, p < 0.001; Figure 4F).","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:Q6PIR6:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"Analysis of TCGA-LUAD data revealed a significant positive correlation between PSMD14 and HMMR expression in clinical specimens (r = 0.56, p < 0.001; Figure 4F).","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:Q6PIR6:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"Analysis of TCGA-LUAD data revealed a significant positive correlation between PSMD14 and HMMR expression in clinical specimens (r = 0.56, p < 0.001; Figure 4F).","confidence":0.8,"supports":true}
{"relationship_key":"prov:972c8b7f467f4bc8b786c75bf96b4799:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_35","section":null,"start_offset":0,"end_offset":0,"text_span":"PSMD14 preferentially removes K63-linked ubiquitin chains from HMMR (Supplementary Figure S1F).","confidence":0.7,"supports":true}
{"relationship_key":"prov:972c8b7f467f4bc8b786c75bf96b4799:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_35","section":null,"start_offset":0,"end_offset":0,"text_span":"PSMD14 preferentially removes K63-linked ubiquitin chains from HMMR (Supplementary Figure S1F).","confidence":0.7,"supports":true}
{"relationship_key":"prov:972c8b7f467f4bc8b786c75bf96b4799:indicates:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"these data demonstrate that PSMD14 stabilizes HMMR through a deubiquitination mechanism that predominantly targets K63-linked ubiquitin chains.","confidence":0.9,"supports":true}
{"relationship_key":"prov:972c8b7f467f4bc8b786c75bf96b4799:indicates:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"these data demonstrate that PSMD14 stabilizes HMMR through a deubiquitination mechanism that predominantly targets K63-linked ubiquitin chains.","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Cycloheximide:treats:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"(A, B) Cycloheximide (CHX) chase assays show that PSMD14 knockdown reduces while its overexpression extends the half-life of HMMR protein in LUAD cells.","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Cycloheximide:treats:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"(A, B) Cycloheximide (CHX) chase assays show that PSMD14 knockdown reduces while its overexpression extends the half-life of HMMR protein in LUAD cells.","confidence":0.7,"supports":true}
{"relationship_key":"prov:e51e2693aaf2469fabf45c7eeb013046:diagnosed_by:prov:7d60a3da150e431899e5ba55c3bcbe87","document_id":"PMC12757429_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"To further investigate the biological function of PSMD14 in LUAD progression,","confidence":0.9,"supports":true}
{"relationship_key":"prov:e51e2693aaf2469fabf45c7eeb013046:diagnosed_by:prov:7d60a3da150e431899e5ba55c3bcbe87","document_id":"PMC12757429_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"To further investigate the biological function of PSMD14 in LUAD progression,","confidence":0.9,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:diagnosed_by:prov:35f3d61532544074a21560303bec8630","document_id":"PMC12757429_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"Panel E shows the flow cytometric analysis of cell cycle distribution following PSMD14 knockdown in LUAD cells.","confidence":1.0,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:diagnosed_by:prov:35f3d61532544074a21560303bec8630","document_id":"PMC12757429_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"Panel E shows the flow cytometric analysis of cell cycle distribution following PSMD14 knockdown in LUAD cells.","confidence":1.0,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:affects:MeSH:D004249","document_id":"PMC12757429_window_41","section":null,"start_offset":0,"end_offset":0,"text_span":"PSMD14 regulates DNA damage repair in LUAD.","confidence":0.9,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:affects:MeSH:D004249","document_id":"PMC12757429_window_41","section":null,"start_offset":0,"end_offset":0,"text_span":"PSMD14 regulates DNA damage repair in LUAD.","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:A0A5C6NN77:indicates:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_41","section":null,"start_offset":0,"end_offset":0,"text_span":"Panel C shows Western blots for Vimentin, N-Cadherin, E-Cadherin, MMP2, and GAPDH in H1299 and H1975 cells.","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:A0A5C6NN77:indicates:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_41","section":null,"start_offset":0,"end_offset":0,"text_span":"Panel C shows Western blots for Vimentin, N-Cadherin, E-Cadherin, MMP2, and GAPDH in H1299 and H1975 cells.","confidence":0.8,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:affects:DBPedia:Apoptosis","document_id":"PMC12757429_window_46","section":null,"start_offset":0,"end_offset":0,"text_span":"Capzimin suppresses colony formation and induces mitochondrial-mediated apoptosis in LUAD cells.","confidence":0.7,"supports":true}
{"relationship_key":"prov:ea72372a5a0048f88966bc68df24d849:affects:DBPedia:Apoptosis","document_id":"PMC12757429_window_46","section":null,"start_offset":0,"end_offset":0,"text_span":"Capzimin suppresses colony formation and induces mitochondrial-mediated apoptosis in LUAD cells.","confidence":0.7,"supports":true}
{"relationship_key":"prov:e51e2693aaf2469fabf45c7eeb013046:associated_with:prov:64a91bc0349248bbb5aa8fa0fb1dfb64","document_id":"PMC12757429_window_50","section":null,"start_offset":0,"end_offset":0,"text_span":"activating TGF-β/Smad and PI3K/AKT/mTOR signaling pathways","confidence":0.6,"supports":true}
{"relationship_key":"prov:e51e2693aaf2469fabf45c7eeb013046:associated_with:prov:64a91bc0349248bbb5aa8fa0fb1dfb64","document_id":"PMC12757429_window_50","section":null,"start_offset":0,"end_offset":0,"text_span":"activating TGF-β/Smad and PI3K/AKT/mTOR signaling pathways","confidence":0.6,"supports":true}
{"relationship_key":"prov:972c8b7f467f4bc8b786c75bf96b4799:associated_with:prov:7626a6dd3be7433a93236039216c7fc6","document_id":"PMC12757429_window_52","section":null,"start_offset":0,"end_offset":0,"text_span":"stabilizing oncogenic substrates via K63-linked deubiquitination","confidence":0.5,"supports":true}
{"relationship_key":"prov:972c8b7f467f4bc8b786c75bf96b4799:associated_with:prov:7626a6dd3be7433a93236039216c7fc6","document_id":"PMC12757429_window_52","section":null,"start_offset":0,"end_offset":0,"text_span":"stabilizing oncogenic substrates via K63-linked deubiquitination","confidence":0.5,"supports":true}
{"relationship_key":"prov:96d5f09b7d8c44d7b33404f9be7d5fa1:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_54","section":null,"start_offset":0,"end_offset":0,"text_span":"More importantly, our study reveals that the PSMD14-HMMR axis represents a distinct and integrative oncogenic mechanism in LUAD.","confidence":0.9,"supports":true}
{"relationship_key":"prov:96d5f09b7d8c44d7b33404f9be7d5fa1:associated_with:prov:ea72372a5a0048f88966bc68df24d849","document_id":"PMC12757429_window_54","section":null,"start_offset":0,"end_offset":0,"text_span":"More importantly, our study reveals that the PSMD14-HMMR axis represents a distinct and integrative oncogenic mechanism in LUAD.","confidence":0.9,"supports":true}
{"relationship_key":"prov:b304e22a489448a18a31605df97132ff:indicates:DBPedia:Small_Cell_Lung_Cancer","document_id":"PMC12757875_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"To address this gap, we developed the DDR-Immune Fitness (DDR-IF) score-a composite biomarker that integrates measures of genomic instability (homologous recombination deficiency [HRD] and tumor mutational burden [TMB]) with immune contexture (STING pathway activation)","confidence":0.7,"supports":true}
{"relationship_key":"prov:b304e22a489448a18a31605df97132ff:indicates:DBPedia:Small_Cell_Lung_Cancer","document_id":"PMC12757875_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"To address this gap, we developed the DDR-Immune Fitness (DDR-IF) score-a composite biomarker that integrates measures of genomic instability (homologous recombination deficiency [HRD] and tumor mutational burden [TMB]) with immune contexture (STING pathway activation)","confidence":0.7,"supports":true}
{"relationship_key":"prov:95c5a0501fbb4563bd3134c07927a67b:associated_with:prov:26d2fb1e89b7464fa3ff9286022d4559","document_id":"PMC12757875_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"The score directly addresses the urgent need for a composite biomarker that integrates genomic (HRD, TMB) and immune (STING activation) dimensions","confidence":0.7,"supports":true}
{"relationship_key":"prov:95c5a0501fbb4563bd3134c07927a67b:associated_with:prov:26d2fb1e89b7464fa3ff9286022d4559","document_id":"PMC12757875_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"The score directly addresses the urgent need for a composite biomarker that integrates genomic (HRD, TMB) and immune (STING activation) dimensions","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Small_Cell_Lung_Cancer:diagnosed_by:DBPedia:RNA-Seq","document_id":"PMC12757875_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"To derive the biomarker, we integrated single-cell RNA sequencing (scRNA-seq) data from 82 treatment-naïve SCLC tumors","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Small_Cell_Lung_Cancer:diagnosed_by:DBPedia:RNA-Seq","document_id":"PMC12757875_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"To derive the biomarker, we integrated single-cell RNA sequencing (scRNA-seq) data from 82 treatment-naïve SCLC tumors","confidence":0.8,"supports":true}
{"relationship_key":"prov:07601dca79254f5dbf8faeef85738925:associated_with:MeSH:D007167","document_id":"PMC12757875_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"The search strategy used a combination of keywords and MeSH terms related to “small cell lung cancer,” “PARP inhibitor,” “immunotherapy,” and “clinical trial.”","confidence":0.7,"supports":true}
{"relationship_key":"prov:07601dca79254f5dbf8faeef85738925:associated_with:MeSH:D007167","document_id":"PMC12757875_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"The search strategy used a combination of keywords and MeSH terms related to “small cell lung cancer,” “PARP inhibitor,” “immunotherapy,” and “clinical trial.”","confidence":0.7,"supports":true}
{"relationship_key":"prov:95c5a0501fbb4563bd3134c07927a67b:indicates:prov:5835ca5fefa0401687b27b6b5038b8ab","document_id":"PMC12757875_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"A cut-off value of ≥0.65 for defining “DDR-IF-high” status was determined by maximizing Youden’s index in the training cohort.","confidence":1.0,"supports":true}
{"relationship_key":"prov:95c5a0501fbb4563bd3134c07927a67b:indicates:prov:5835ca5fefa0401687b27b6b5038b8ab","document_id":"PMC12757875_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"A cut-off value of ≥0.65 for defining “DDR-IF-high” status was determined by maximizing Youden’s index in the training cohort.","confidence":1.0,"supports":true}
{"relationship_key":"HGNC:26115:indicates:prov:5835ca5fefa0401687b27b6b5038b8ab","document_id":"PMC12757875_window_11","section":null,"start_offset":0,"end_offset":0,"text_span":"mutations in BRCA1/2 and PARP1 amplification correlate with genomic instability, which is directly quantified by the HRD metric","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:26115:indicates:prov:5835ca5fefa0401687b27b6b5038b8ab","document_id":"PMC12757875_window_11","section":null,"start_offset":0,"end_offset":0,"text_span":"mutations in BRCA1/2 and PARP1 amplification correlate with genomic instability, which is directly quantified by the HRD metric","confidence":0.9,"supports":true}
{"relationship_key":"prov:95c5a0501fbb4563bd3134c07927a67b:indicates:prov:f9418500897240c6adf20f6279d4ea58","document_id":"PMC12757875_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"In our cohort, the DDR-IF score demonstrated superior predictive power for PARP-ICB response (AUROC = 0.81)","confidence":0.9,"supports":true}
{"relationship_key":"prov:95c5a0501fbb4563bd3134c07927a67b:indicates:prov:f9418500897240c6adf20f6279d4ea58","document_id":"PMC12757875_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"In our cohort, the DDR-IF score demonstrated superior predictive power for PARP-ICB response (AUROC = 0.81)","confidence":0.9,"supports":true}
{"relationship_key":"prov:c3c72d412000409680668d6911bd1fe2:indicates:prov:66d424206d3d4c08aed820a9ccdeaad1","document_id":"PMC12757875_window_13","section":null,"start_offset":0,"end_offset":0,"text_span":"Multiplex-IF (n=82) demonstrated that PARP1-high tumors (H-score ≥150) exhibited 2.3-fold fewer CD8+ TILs (p=0.004) and diminished p-STING (<5% area), indicating immune-cold phenotypes","confidence":0.9,"supports":true}
{"relationship_key":"prov:c3c72d412000409680668d6911bd1fe2:indicates:prov:66d424206d3d4c08aed820a9ccdeaad1","document_id":"PMC12757875_window_13","section":null,"start_offset":0,"end_offset":0,"text_span":"Multiplex-IF (n=82) demonstrated that PARP1-high tumors (H-score ≥150) exhibited 2.3-fold fewer CD8+ TILs (p=0.004) and diminished p-STING (<5% area), indicating immune-cold phenotypes","confidence":0.9,"supports":true}
{"relationship_key":"prov:95c5a0501fbb4563bd3134c07927a67b:supports:prov:66d424206d3d4c08aed820a9ccdeaad1","document_id":"PMC12757875_window_13","section":null,"start_offset":0,"end_offset":0,"text_span":"The DDR-IF score, which integrates specific DDR alterations (contributing to the HRD component) with key TME features","confidence":0.8,"supports":true}
{"relationship_key":"prov:95c5a0501fbb4563bd3134c07927a67b:supports:prov:66d424206d3d4c08aed820a9ccdeaad1","document_id":"PMC12757875_window_13","section":null,"start_offset":0,"end_offset":0,"text_span":"The DDR-IF score, which integrates specific DDR alterations (contributing to the HRD component) with key TME features","confidence":0.8,"supports":true}
{"relationship_key":"prov:b560ddef6a2b4b7693499c3fed39ea64:treats:prov:07601dca79254f5dbf8faeef85738925","document_id":"PMC12757875_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"why SCLC tumors with high genomic instability (a source of neoantigens) can remain refractory to ICB monotherapy","confidence":0.9,"supports":true}
{"relationship_key":"prov:b560ddef6a2b4b7693499c3fed39ea64:treats:prov:07601dca79254f5dbf8faeef85738925","document_id":"PMC12757875_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"why SCLC tumors with high genomic instability (a source of neoantigens) can remain refractory to ICB monotherapy","confidence":0.9,"supports":true}
{"relationship_key":"prov:26d2fb1e89b7464fa3ff9286022d4559:indicates:prov:5835ca5fefa0401687b27b6b5038b8ab","document_id":"PMC12757875_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"The STING activation component of the DDR-IF score quantifies this exhaustion, identifying tumors with crippled innate immune sensing-a hallmark of the DDR-IF-high subgroup","confidence":0.8,"supports":true}
{"relationship_key":"prov:26d2fb1e89b7464fa3ff9286022d4559:indicates:prov:5835ca5fefa0401687b27b6b5038b8ab","document_id":"PMC12757875_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"The STING activation component of the DDR-IF score quantifies this exhaustion, identifying tumors with crippled innate immune sensing-a hallmark of the DDR-IF-high subgroup","confidence":0.8,"supports":true}
{"relationship_key":"prov:cffbfe61fdde46cd854d73d9964a3dee:associated_with:prov:5835ca5fefa0401687b27b6b5038b8ab","document_id":"PMC12757875_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"Our findings clarify a central paradox: why SCLC tumors with high genomic instability (a source of neoantigens) can remain refractory to ICB monotherapy-they lack the functional innate immune sensing apparatus necessary","confidence":0.7,"supports":true}
{"relationship_key":"prov:cffbfe61fdde46cd854d73d9964a3dee:associated_with:prov:5835ca5fefa0401687b27b6b5038b8ab","document_id":"PMC12757875_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"Our findings clarify a central paradox: why SCLC tumors with high genomic instability (a source of neoantigens) can remain refractory to ICB monotherapy-they lack the functional innate immune sensing apparatus necessary","confidence":0.7,"supports":true}
{"relationship_key":"prov:07601dca79254f5dbf8faeef85738925:diagnosed_by:prov:795ae93456614f00adcb3f8c06513aa7","document_id":"PMC12757875_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"This results in a profoundly interferon-desert TME with scant CD8+ T cell infiltration, effectively creating an ‘immunologically cold’ tumor","confidence":0.6,"supports":true}
{"relationship_key":"prov:07601dca79254f5dbf8faeef85738925:diagnosed_by:prov:795ae93456614f00adcb3f8c06513aa7","document_id":"PMC12757875_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"This results in a profoundly interferon-desert TME with scant CD8+ T cell infiltration, effectively creating an ‘immunologically cold’ tumor","confidence":0.6,"supports":true}
{"relationship_key":"prov:4ae4f041a06140dd872ce87717d930f3:interacts_with:prov:b560ddef6a2b4b7693499c3fed39ea64","document_id":"PMC12757875_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"combination therapies (e.g., PARPi + anti-PD-L1) that aim to reverse this state","confidence":0.5,"supports":true}
{"relationship_key":"prov:4ae4f041a06140dd872ce87717d930f3:interacts_with:prov:b560ddef6a2b4b7693499c3fed39ea64","document_id":"PMC12757875_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"combination therapies (e.g., PARPi + anti-PD-L1) that aim to reverse this state","confidence":0.5,"supports":true}
{"relationship_key":"DBPedia:Warburg_effect_(oncology):part_of:prov:5e6cf365fa5c4ed39cb256d7e97a24e3","document_id":"PMC12757875_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"SCLC cells with DDR pathway abnormalities often exhibit a heightened glycolytic phenotype, known as the Warburg effect","confidence":0.6,"supports":true}
{"relationship_key":"DBPedia:Warburg_effect_(oncology):part_of:prov:5e6cf365fa5c4ed39cb256d7e97a24e3","document_id":"PMC12757875_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"SCLC cells with DDR pathway abnormalities often exhibit a heightened glycolytic phenotype, known as the Warburg effect","confidence":0.6,"supports":true}
{"relationship_key":"DBPedia:Ligand:targets:UniProt:A0AC11D5X2","document_id":"PMC12757875_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"phosphorylates and stabilizes the TIGIT ligands CD155 and CD112","confidence":1.0,"supports":true}
{"relationship_key":"DBPedia:Ligand:targets:UniProt:A0AC11D5X2","document_id":"PMC12757875_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"phosphorylates and stabilizes the TIGIT ligands CD155 and CD112","confidence":1.0,"supports":true}
{"relationship_key":"prov:5835ca5fefa0401687b27b6b5038b8ab:diagnosed_by:prov:a7c4876a8436429b950c1a54c93628b1","document_id":"PMC12757875_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"advises PARP-ICB therapy for DDR-IF-High and standard chemotherapy for DDR-IF-Low","confidence":0.8,"supports":true}
{"relationship_key":"prov:5835ca5fefa0401687b27b6b5038b8ab:diagnosed_by:prov:a7c4876a8436429b950c1a54c93628b1","document_id":"PMC12757875_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"advises PARP-ICB therapy for DDR-IF-High and standard chemotherapy for DDR-IF-Low","confidence":0.8,"supports":true}
{"relationship_key":"RxNorm:1918231:treats:prov:3e5b6f7392b641d19b5a33e489c8b4a9","document_id":"PMC12757875_window_26","section":null,"start_offset":0,"end_offset":0,"text_span":"Combining niraparib with radiotherapy activates the cGAS/STING pathway and increases PD-L1 expression","confidence":0.8,"supports":true}
{"relationship_key":"RxNorm:1918231:treats:prov:3e5b6f7392b641d19b5a33e489c8b4a9","document_id":"PMC12757875_window_26","section":null,"start_offset":0,"end_offset":0,"text_span":"Combining niraparib with radiotherapy activates the cGAS/STING pathway and increases PD-L1 expression","confidence":0.8,"supports":true}
{"relationship_key":"prov:c634b55e30984a0faf6a230558d4f699:associated_with:prov:5835ca5fefa0401687b27b6b5038b8ab","document_id":"PMC12757875_window_26","section":null,"start_offset":0,"end_offset":0,"text_span":"recruiting effector T-cells into the TME through the release of DAMPs and type I interferon-responsive chemokines (e.g., CXCL10)","confidence":0.7,"supports":true}
{"relationship_key":"prov:c634b55e30984a0faf6a230558d4f699:associated_with:prov:5835ca5fefa0401687b27b6b5038b8ab","document_id":"PMC12757875_window_26","section":null,"start_offset":0,"end_offset":0,"text_span":"recruiting effector T-cells into the TME through the release of DAMPs and type I interferon-responsive chemokines (e.g., CXCL10)","confidence":0.7,"supports":true}
{"relationship_key":"prov:c634b55e30984a0faf6a230558d4f699:associated_with:prov:3e5b6f7392b641d19b5a33e489c8b4a9","document_id":"PMC12757875_window_26","section":null,"start_offset":0,"end_offset":0,"text_span":"recruiting effector T-cells into the TME through the release of DAMPs and type I interferon-responsive chemokines (e.g., CXCL10)","confidence":0.7,"supports":true}
{"relationship_key":"prov:c634b55e30984a0faf6a230558d4f699:associated_with:prov:3e5b6f7392b641d19b5a33e489c8b4a9","document_id":"PMC12757875_window_26","section":null,"start_offset":0,"end_offset":0,"text_span":"recruiting effector T-cells into the TME through the release of DAMPs and type I interferon-responsive chemokines (e.g., CXCL10)","confidence":0.7,"supports":true}
{"relationship_key":"prov:01629fd7dae54d3c80042d8062c9b0fb:associated_with:prov:ec4bed1910214b11bf17b01139849576","document_id":"PMC12757875_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"10% of patients exhibited primary resistance, associated with TIGIT/VISTA co-expression","confidence":0.9,"supports":true}
{"relationship_key":"prov:01629fd7dae54d3c80042d8062c9b0fb:associated_with:prov:ec4bed1910214b11bf17b01139849576","document_id":"PMC12757875_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"10% of patients exhibited primary resistance, associated with TIGIT/VISTA co-expression","confidence":0.9,"supports":true}
{"relationship_key":"prov:d0f51139c521491c86a0a5f3f96828e1:associated_with:prov:ec4bed1910214b11bf17b01139849576","document_id":"PMC12757875_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"10% of patients exhibited primary resistance, associated with TIGIT/VISTA co-expression or HLA loss of heterozygosity","confidence":0.9,"supports":true}
{"relationship_key":"prov:d0f51139c521491c86a0a5f3f96828e1:associated_with:prov:ec4bed1910214b11bf17b01139849576","document_id":"PMC12757875_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"10% of patients exhibited primary resistance, associated with TIGIT/VISTA co-expression or HLA loss of heterozygosity","confidence":0.9,"supports":true}
{"relationship_key":"prov:f9418500897240c6adf20f6279d4ea58:diagnosed_by:MeSH:D005434","document_id":"PMC12757875_window_33","section":null,"start_offset":0,"end_offset":0,"text_span":"Immunohistochemistry was performed on cell blocks.","confidence":0.9,"supports":true}
{"relationship_key":"prov:f9418500897240c6adf20f6279d4ea58:diagnosed_by:MeSH:D005434","document_id":"PMC12757875_window_33","section":null,"start_offset":0,"end_offset":0,"text_span":"Immunohistochemistry was performed on cell blocks.","confidence":0.9,"supports":true}
{"relationship_key":"prov:c3c72d412000409680668d6911bd1fe2:indicates:prov:f9418500897240c6adf20f6279d4ea58","document_id":"PMC12757875_window_33","section":null,"start_offset":0,"end_offset":0,"text_span":"orthogonal STING validation (e.g., phospho-flow cytometry for p-STING)","confidence":0.8,"supports":true}
{"relationship_key":"prov:c3c72d412000409680668d6911bd1fe2:indicates:prov:f9418500897240c6adf20f6279d4ea58","document_id":"PMC12757875_window_33","section":null,"start_offset":0,"end_offset":0,"text_span":"orthogonal STING validation (e.g., phospho-flow cytometry for p-STING)","confidence":0.8,"supports":true}
{"relationship_key":"prov:b560ddef6a2b4b7693499c3fed39ea64:treats:prov:5835ca5fefa0401687b27b6b5038b8ab","document_id":"PMC12757875_window_35","section":null,"start_offset":0,"end_offset":0,"text_span":"why tumors with high genomic instability (e.g., elevated HRD/TMB) can remain refractory to ICB monotherapy-they lack the functional innate immune sensing apparatus necessary to initiate an adaptive anti-tumor response.","confidence":0.9,"supports":true}
{"relationship_key":"prov:b560ddef6a2b4b7693499c3fed39ea64:treats:prov:5835ca5fefa0401687b27b6b5038b8ab","document_id":"PMC12757875_window_35","section":null,"start_offset":0,"end_offset":0,"text_span":"why tumors with high genomic instability (e.g., elevated HRD/TMB) can remain refractory to ICB monotherapy-they lack the functional innate immune sensing apparatus necessary to initiate an adaptive anti-tumor response.","confidence":0.9,"supports":true}
{"relationship_key":"prov:26e12d45643a45eb90a3d4abcd83e387:targets:prov:cffbfe61fdde46cd854d73d9964a3dee","document_id":"PMC12757875_window_35","section":null,"start_offset":0,"end_offset":0,"text_span":"pharmacological STING agonists could be employed to directly reverse the pathway exhaustion and re-sensitize these immunologically cold tumors to checkpoint blockade","confidence":0.5,"supports":true}
{"relationship_key":"prov:26e12d45643a45eb90a3d4abcd83e387:targets:prov:cffbfe61fdde46cd854d73d9964a3dee","document_id":"PMC12757875_window_35","section":null,"start_offset":0,"end_offset":0,"text_span":"pharmacological STING agonists could be employed to directly reverse the pathway exhaustion and re-sensitize these immunologically cold tumors to checkpoint blockade","confidence":0.5,"supports":true}
{"relationship_key":"prov:95c5a0501fbb4563bd3134c07927a67b:indicates:prov:07601dca79254f5dbf8faeef85738925","document_id":"PMC12757875_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"The DDR-IF score integrates genomic instability and immune contexture to identify ES-SCLC tumors most susceptible to PARP-ICB synergy.","confidence":0.9,"supports":true}
{"relationship_key":"prov:95c5a0501fbb4563bd3134c07927a67b:indicates:prov:07601dca79254f5dbf8faeef85738925","document_id":"PMC12757875_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"The DDR-IF score integrates genomic instability and immune contexture to identify ES-SCLC tumors most susceptible to PARP-ICB synergy.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D016889:indicates:MeSH:D042822","document_id":"PMC12764803_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"Integrating HRD-based genomic instability metrics with molecular and immune profiling supports precision oncology in endometrial cancer.","confidence":0.7,"supports":true}
{"relationship_key":"MeSH:D016889:indicates:MeSH:D042822","document_id":"PMC12764803_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"Integrating HRD-based genomic instability metrics with molecular and immune profiling supports precision oncology in endometrial cancer.","confidence":0.7,"supports":true}
{"relationship_key":"prov:12df81e9d4e64e9f928256157270f092:associated_with:MeSH:D042822","document_id":"PMC12764803_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"HRD may also contribute to elevated tumour mutational burden and immune microenvironment variability","confidence":0.7,"supports":true}
{"relationship_key":"prov:12df81e9d4e64e9f928256157270f092:associated_with:MeSH:D042822","document_id":"PMC12764803_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"HRD may also contribute to elevated tumour mutational burden and immune microenvironment variability","confidence":0.7,"supports":true}
{"relationship_key":"prov:12df81e9d4e64e9f928256157270f092:indicates:MeSH:D042822","document_id":"PMC12764803_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"HRD may also contribute to elevated tumour mutational burden and immune microenvironment variability","confidence":0.6,"supports":true}
{"relationship_key":"prov:12df81e9d4e64e9f928256157270f092:indicates:MeSH:D042822","document_id":"PMC12764803_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"HRD may also contribute to elevated tumour mutational burden and immune microenvironment variability","confidence":0.6,"supports":true}
{"relationship_key":"MeSH:D018269:indicates:prov:7659ea4d108749368041739a8ecc1f99","document_id":"PMC12764803_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"The majority of cases (84.5%) were endometrioid, while 6 (4.2%) were serous,","confidence":0.5,"supports":true}
{"relationship_key":"MeSH:D018269:indicates:prov:7659ea4d108749368041739a8ecc1f99","document_id":"PMC12764803_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"The majority of cases (84.5%) were endometrioid, while 6 (4.2%) were serous,","confidence":0.5,"supports":true}
{"relationship_key":"MeSH:D012704:indicates:prov:7659ea4d108749368041739a8ecc1f99","document_id":"PMC12764803_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"The majority of cases (84.5%) were endometrioid, while 6 (4.2%) were serous,","confidence":0.4,"supports":true}
{"relationship_key":"MeSH:D012704:indicates:prov:7659ea4d108749368041739a8ecc1f99","document_id":"PMC12764803_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"The majority of cases (84.5%) were endometrioid, while 6 (4.2%) were serous,","confidence":0.4,"supports":true}
{"relationship_key":"MeSH:D018227:indicates:MeSH:D012704","document_id":"PMC12764803_window_18","section":null,"start_offset":0,"end_offset":0,"text_span":"Clear cell4 (2.8)2 (16.7)1 (1.9)1 (1.3)","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D018227:indicates:MeSH:D012704","document_id":"PMC12764803_window_18","section":null,"start_offset":0,"end_offset":0,"text_span":"Clear cell4 (2.8)2 (16.7)1 (1.9)1 (1.3)","confidence":0.8,"supports":true}
{"relationship_key":"prov:40f97661304a4cb2b3fa3ec838138e22:indicates:MeSH:D016889","document_id":"PMC12764803_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"strongly positively correlated with genomic instability markers, such as SCIN (R = 0.","confidence":1.0,"supports":true}
{"relationship_key":"prov:40f97661304a4cb2b3fa3ec838138e22:indicates:MeSH:D016889","document_id":"PMC12764803_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"strongly positively correlated with genomic instability markers, such as SCIN (R = 0.","confidence":1.0,"supports":true}
{"relationship_key":"prov:3ae622efd84e4e56b0eec88c729e6473:associated_with:prov:5a9b4db05e01454e9212ef4c1f436f9c","document_id":"PMC12764803_window_22","section":null,"start_offset":0,"end_offset":0,"text_span":"The HRD-middle group (n = 53) had the highest proportion of MSI-H and TP53-wt patients (30% each),","confidence":0.8,"supports":true}
{"relationship_key":"prov:3ae622efd84e4e56b0eec88c729e6473:associated_with:prov:5a9b4db05e01454e9212ef4c1f436f9c","document_id":"PMC12764803_window_22","section":null,"start_offset":0,"end_offset":0,"text_span":"The HRD-middle group (n = 53) had the highest proportion of MSI-H and TP53-wt patients (30% each),","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Macrophage:associated_with:prov:5a9b4db05e01454e9212ef4c1f436f9c","document_id":"PMC12764803_window_27","section":null,"start_offset":0,"end_offset":0,"text_span":"higher densities of CD3+ T cells (in both parenchyma and stroma), CD8+ T cells (in parenchyma), M1 macrophages (in parenchyma)","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Macrophage:associated_with:prov:5a9b4db05e01454e9212ef4c1f436f9c","document_id":"PMC12764803_window_27","section":null,"start_offset":0,"end_offset":0,"text_span":"higher densities of CD3+ T cells (in both parenchyma and stroma), CD8+ T cells (in parenchyma), M1 macrophages (in parenchyma)","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Chemoradiotherapy:treats:DBPedia:Uterine_serous_carcinoma","document_id":"PMC12764803_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"For instance, multiple patients with serous carcinoma, FIGO stage III disease, and TP53 mutations received standard chemoradiotherapy.","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Chemoradiotherapy:treats:DBPedia:Uterine_serous_carcinoma","document_id":"PMC12764803_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"For instance, multiple patients with serous carcinoma, FIGO stage III disease, and TP53 mutations received standard chemoradiotherapy.","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Chemoradiotherapy:treats:MeSH:D012704","document_id":"PMC12764803_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"For instance, multiple patients with serous carcinoma, FIGO stage III disease, and TP53 mutations received standard chemoradiotherapy.","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Chemoradiotherapy:treats:MeSH:D012704","document_id":"PMC12764803_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"For instance, multiple patients with serous carcinoma, FIGO stage III disease, and TP53 mutations received standard chemoradiotherapy.","confidence":0.9,"supports":true}
{"relationship_key":"prov:0d429e85b0d94d8093677768b343ba59:indicates:MeSH:D010051","document_id":"PMC12764803_window_33","section":null,"start_offset":0,"end_offset":0,"text_span":"HRD-driven genomic instability is known to increase tumour mutational burden and neoantigen generation, which may promote immune cell infiltration in ovarian cancer","confidence":0.7,"supports":true}
{"relationship_key":"prov:0d429e85b0d94d8093677768b343ba59:indicates:MeSH:D010051","document_id":"PMC12764803_window_33","section":null,"start_offset":0,"end_offset":0,"text_span":"HRD-driven genomic instability is known to increase tumour mutational burden and neoantigen generation, which may promote immune cell infiltration in ovarian cancer","confidence":0.7,"supports":true}
{"relationship_key":"prov:12df81e9d4e64e9f928256157270f092:indicates:MeSH:D010051","document_id":"PMC12764803_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"HRD-driven genomic instability is known to increase tumour mutational burden and neoantigen generation, which may promote immune cell infiltration.","confidence":0.9,"supports":true}
{"relationship_key":"prov:12df81e9d4e64e9f928256157270f092:indicates:MeSH:D010051","document_id":"PMC12764803_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"HRD-driven genomic instability is known to increase tumour mutational burden and neoantigen generation, which may promote immune cell infiltration.","confidence":0.9,"supports":true}
{"relationship_key":"prov:86a18df2da5a4684a93242f84339de4b:associated_with:MeSH:D010051","document_id":"PMC12764803_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"These findings suggest that HRD-High ECs may represent a subset of tumours with potential responsiveness to immune checkpoint inhibitors, particularly when used in combination with DNA damage-targeted therapies.","confidence":0.7,"supports":true}
{"relationship_key":"prov:86a18df2da5a4684a93242f84339de4b:associated_with:MeSH:D010051","document_id":"PMC12764803_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"These findings suggest that HRD-High ECs may represent a subset of tumours with potential responsiveness to immune checkpoint inhibitors, particularly when used in combination with DNA damage-targeted therapies.","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Adjuvant_therapy:treats:MeSH:D010051","document_id":"PMC12764803_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"Despite receiving standard adjuvant therapy, patients with HRD-High tumours experienced disproportionately high recurrence rates","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Adjuvant_therapy:treats:MeSH:D010051","document_id":"PMC12764803_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"Despite receiving standard adjuvant therapy, patients with HRD-High tumours experienced disproportionately high recurrence rates","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D012515:diagnosed_by:prov:e18e9adad6614e7f93c59e97e7c4997d","document_id":"PMC12775561_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"This study evaluated its utility compared to a conventional DNA‐only test (FoundationOne CDx) in managing sarcoma patients","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D012515:diagnosed_by:prov:e18e9adad6614e7f93c59e97e7c4997d","document_id":"PMC12775561_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"This study evaluated its utility compared to a conventional DNA‐only test (FoundationOne CDx) in managing sarcoma patients","confidence":0.9,"supports":true}
{"relationship_key":"prov:b148ab31f219431cb3f79c967328e0c9:targets:prov:68eec6a8055d46e7a1510da3fbae1f69","document_id":"PMC12775561_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions","confidence":0.8,"supports":true}
{"relationship_key":"prov:b148ab31f219431cb3f79c967328e0c9:targets:prov:68eec6a8055d46e7a1510da3fbae1f69","document_id":"PMC12775561_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions","confidence":0.8,"supports":true}
{"relationship_key":"prov:e18e9adad6614e7f93c59e97e7c4997d:targets:prov:68eec6a8055d46e7a1510da3fbae1f69","document_id":"PMC12775561_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions","confidence":0.8,"supports":true}
{"relationship_key":"prov:e18e9adad6614e7f93c59e97e7c4997d:targets:prov:68eec6a8055d46e7a1510da3fbae1f69","document_id":"PMC12775561_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions","confidence":0.8,"supports":true}
{"relationship_key":"prov:baf50864f2334df8918600cf4ced14a2:indicates:MeSH:D012515","document_id":"PMC12775561_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Additionally, 5.7% of patients had pathogenic germline variants identified through tumor–normal matched analysis.","confidence":0.8,"supports":true}
{"relationship_key":"prov:baf50864f2334df8918600cf4ced14a2:indicates:MeSH:D012515","document_id":"PMC12775561_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Additionally, 5.7% of patients had pathogenic germline variants identified through tumor–normal matched analysis.","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D012515:diagnosed_by:prov:1c24a2502587444c8eaa6f16c9db1348","document_id":"PMC12775561_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"NGS-based comprehensive cancer genomic profiling (CGP) tests are now widely implemented in clinical practice","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D012515:diagnosed_by:prov:1c24a2502587444c8eaa6f16c9db1348","document_id":"PMC12775561_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"NGS-based comprehensive cancer genomic profiling (CGP) tests are now widely implemented in clinical practice","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D012515:diagnosed_by:prov:5b6f9b44f63b4ebc9560014c4e2eba5b","document_id":"PMC12775561_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"NGS-based comprehensive cancer genomic profiling (CGP) tests are now widely implemented in clinical practice","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D012515:diagnosed_by:prov:5b6f9b44f63b4ebc9560014c4e2eba5b","document_id":"PMC12775561_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"NGS-based comprehensive cancer genomic profiling (CGP) tests are now widely implemented in clinical practice","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D007890:diagnosed_by:prov:1c24a2502587444c8eaa6f16c9db1348","document_id":"PMC12775561_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"NGS-based comprehensive cancer genomic profiling (CGP) tests are now widely implemented in clinical practice","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D007890:diagnosed_by:prov:1c24a2502587444c8eaa6f16c9db1348","document_id":"PMC12775561_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"NGS-based comprehensive cancer genomic profiling (CGP) tests are now widely implemented in clinical practice","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D007890:diagnosed_by:prov:5b6f9b44f63b4ebc9560014c4e2eba5b","document_id":"PMC12775561_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"NGS-based comprehensive cancer genomic profiling (CGP) tests are now widely implemented in clinical practice","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D007890:diagnosed_by:prov:5b6f9b44f63b4ebc9560014c4e2eba5b","document_id":"PMC12775561_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"NGS-based comprehensive cancer genomic profiling (CGP) tests are now widely implemented in clinical practice","confidence":0.8,"supports":true}
{"relationship_key":"prov:38b3a2d901a042a4bab573db07a1a2b9:diagnoses:prov:1c24a2502587444c8eaa6f16c9db1348","document_id":"PMC12775561_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"Recently, cancer predisposition syndromes (CPS) have gained increased recognition due to the broader use of CGP tests [12, 13].","confidence":0.8,"supports":true}
{"relationship_key":"prov:38b3a2d901a042a4bab573db07a1a2b9:diagnoses:prov:1c24a2502587444c8eaa6f16c9db1348","document_id":"PMC12775561_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"Recently, cancer predisposition syndromes (CPS) have gained increased recognition due to the broader use of CGP tests [12, 13].","confidence":0.8,"supports":true}
{"relationship_key":"prov:1c24a2502587444c8eaa6f16c9db1348:manages:prov:38b3a2d901a042a4bab573db07a1a2b9","document_id":"PMC12775561_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"Recently, cancer predisposition syndromes (CPS) have gained increased recognition due to the broader use of CGP tests [12, 13].","confidence":0.8,"supports":true}
{"relationship_key":"prov:1c24a2502587444c8eaa6f16c9db1348:manages:prov:38b3a2d901a042a4bab573db07a1a2b9","document_id":"PMC12775561_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"Recently, cancer predisposition syndromes (CPS) have gained increased recognition due to the broader use of CGP tests [12, 13].","confidence":0.8,"supports":true}
{"relationship_key":"prov:98ed380ed4014c11bd867bbf784f1d3e:indicates:prov:38b3a2d901a042a4bab573db07a1a2b9","document_id":"PMC12775561_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"CGP tests reportedly play a crucial role in identifying germline alterations, which are detected in 3.3%–16.7% of patients with various malignancies undergoing CGP tests in clinical settings [12, 13].","confidence":0.8,"supports":true}
{"relationship_key":"prov:98ed380ed4014c11bd867bbf784f1d3e:indicates:prov:38b3a2d901a042a4bab573db07a1a2b9","document_id":"PMC12775561_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"CGP tests reportedly play a crucial role in identifying germline alterations, which are detected in 3.3%–16.7% of patients with various malignancies undergoing CGP tests in clinical settings [12, 13].","confidence":0.8,"supports":true}
{"relationship_key":"prov:38b3a2d901a042a4bab573db07a1a2b9:diagnosed_by:prov:5b6f9b44f63b4ebc9560014c4e2eba5b","document_id":"PMC12775561_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"However, most CGP tests utilize tumor‐only sequencing, which cannot distinguish between somatic and germline variants.","confidence":0.8,"supports":true}
{"relationship_key":"prov:38b3a2d901a042a4bab573db07a1a2b9:diagnosed_by:prov:5b6f9b44f63b4ebc9560014c4e2eba5b","document_id":"PMC12775561_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"However, most CGP tests utilize tumor‐only sequencing, which cannot distinguish between somatic and germline variants.","confidence":0.8,"supports":true}
{"relationship_key":"prov:b148ab31f219431cb3f79c967328e0c9:associated_with:MeSH:D012515","document_id":"PMC12775561_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"GenMineTOP is a novel dual DNA–RNA panel that functions as a paired tumor–normal matched test.","confidence":0.6,"supports":true}
{"relationship_key":"prov:b148ab31f219431cb3f79c967328e0c9:associated_with:MeSH:D012515","document_id":"PMC12775561_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"GenMineTOP is a novel dual DNA–RNA panel that functions as a paired tumor–normal matched test.","confidence":0.6,"supports":true}
{"relationship_key":"MeSH:D012515:diagnosed_by:prov:b148ab31f219431cb3f79c967328e0c9","document_id":"PMC12775561_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"The clinical performance of dual DNA–RNA panels, particularly in routine settings, has not yet been evaluated in patients with sarcoma","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D012515:diagnosed_by:prov:b148ab31f219431cb3f79c967328e0c9","document_id":"PMC12775561_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"The clinical performance of dual DNA–RNA panels, particularly in routine settings, has not yet been evaluated in patients with sarcoma","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D012515:associated_with:HGNC:28243","document_id":"PMC12775561_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"their known genetic features: translocation‐related sarcomas (TRS), which are characterized by specific reciprocal translocations resulting in oncogenic fusion transcripts;","confidence":0.5,"supports":true}
{"relationship_key":"MeSH:D012515:associated_with:HGNC:28243","document_id":"PMC12775561_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"their known genetic features: translocation‐related sarcomas (TRS), which are characterized by specific reciprocal translocations resulting in oncogenic fusion transcripts;","confidence":0.5,"supports":true}
{"relationship_key":"MeSH:D012515:indicates:HGNC:28243","document_id":"PMC12775561_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"their known genetic features: translocation‐related sarcomas (TRS), which are characterized by specific reciprocal translocations resulting in oncogenic fusion transcripts;","confidence":0.4,"supports":true}
{"relationship_key":"MeSH:D012515:indicates:HGNC:28243","document_id":"PMC12775561_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"their known genetic features: translocation‐related sarcomas (TRS), which are characterized by specific reciprocal translocations resulting in oncogenic fusion transcripts;","confidence":0.4,"supports":true}
{"relationship_key":"prov:1c24a2502587444c8eaa6f16c9db1348:targets:prov:045c77e8b48840b180c3904bf45c9968","document_id":"PMC12775561_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"F1CDx evaluates 324 genes and identifies single nucleotide variants (SNV), insertions/deletions (indels), and copy number variations (CNV, including amplifications and gains) in 309 genes.","confidence":0.2,"supports":true}
{"relationship_key":"prov:1c24a2502587444c8eaa6f16c9db1348:targets:prov:045c77e8b48840b180c3904bf45c9968","document_id":"PMC12775561_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"F1CDx evaluates 324 genes and identifies single nucleotide variants (SNV), insertions/deletions (indels), and copy number variations (CNV, including amplifications and gains) in 309 genes.","confidence":0.2,"supports":true}
{"relationship_key":"prov:1c24a2502587444c8eaa6f16c9db1348:targets:HGNC:28243","document_id":"PMC12775561_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"F1CDx evaluates 324 genes and identifies single nucleotide variants (SNV), insertions/deletions (indels), and copy number variations (CNV, including amplifications and gains) in 309 genes.","confidence":0.1,"supports":true}
{"relationship_key":"prov:1c24a2502587444c8eaa6f16c9db1348:targets:HGNC:28243","document_id":"PMC12775561_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"F1CDx evaluates 324 genes and identifies single nucleotide variants (SNV), insertions/deletions (indels), and copy number variations (CNV, including amplifications and gains) in 309 genes.","confidence":0.1,"supports":true}
{"relationship_key":"prov:98ed380ed4014c11bd867bbf784f1d3e:associated_with:prov:367da93f77774281b5959b688c336269","document_id":"PMC12775561_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"Among the 40 genes analyzed for germline variants are TP53, RB1, NF1, and BRCA1 (Table S3). Germline alterations were reported as pathogenic or likely pathogenic variants if classified accordingly in the ClinVar or Ambry Genetics databases [25, 26].","confidence":0.9,"supports":true}
{"relationship_key":"prov:98ed380ed4014c11bd867bbf784f1d3e:associated_with:prov:367da93f77774281b5959b688c336269","document_id":"PMC12775561_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"Among the 40 genes analyzed for germline variants are TP53, RB1, NF1, and BRCA1 (Table S3). Germline alterations were reported as pathogenic or likely pathogenic variants if classified accordingly in the ClinVar or Ambry Genetics databases [25, 26].","confidence":0.9,"supports":true}
{"relationship_key":"prov:367da93f77774281b5959b688c336269:associated_with:prov:98ed380ed4014c11bd867bbf784f1d3e","document_id":"PMC12775561_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"Among the 40 genes analyzed for germline variants are TP53, RB1, NF1, and BRCA1 (Table S3). Germline alterations were reported as pathogenic or likely pathogenic variants if classified accordingly in the ClinVar or Ambry Genetics databases [25, 26].","confidence":0.9,"supports":true}
{"relationship_key":"prov:367da93f77774281b5959b688c336269:associated_with:prov:98ed380ed4014c11bd867bbf784f1d3e","document_id":"PMC12775561_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"Among the 40 genes analyzed for germline variants are TP53, RB1, NF1, and BRCA1 (Table S3). Germline alterations were reported as pathogenic or likely pathogenic variants if classified accordingly in the ClinVar or Ambry Genetics databases [25, 26].","confidence":0.9,"supports":true}
{"relationship_key":"prov:9034493c84e74bc1ae00f4f2650e6f25:diagnoses:prov:367da93f77774281b5959b688c336269","document_id":"PMC12775561_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"The clinical significance of the detected gerline variants was interpreted according to the classification guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP)","confidence":0.7,"supports":true}
{"relationship_key":"prov:9034493c84e74bc1ae00f4f2650e6f25:diagnoses:prov:367da93f77774281b5959b688c336269","document_id":"PMC12775561_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"The clinical significance of the detected gerline variants was interpreted according to the classification guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP)","confidence":0.7,"supports":true}
{"relationship_key":"prov:367da93f77774281b5959b688c336269:diagnoses:prov:9034493c84e74bc1ae00f4f2650e6f25","document_id":"PMC12775561_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"The clinical significance of the detected gerline variants was interpreted according to the classification guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP)","confidence":0.7,"supports":true}
{"relationship_key":"prov:367da93f77774281b5959b688c336269:diagnoses:prov:9034493c84e74bc1ae00f4f2650e6f25","document_id":"PMC12775561_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"The clinical significance of the detected gerline variants was interpreted according to the classification guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP)","confidence":0.7,"supports":true}
{"relationship_key":"prov:9034493c84e74bc1ae00f4f2650e6f25:associated_with:prov:68eec6a8055d46e7a1510da3fbae1f69","document_id":"PMC12775561_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"We compared the detection rates of oncogenic gene alterations, including SNV, indels, CNV, and gene fusions, as well as druggable gene alterations, histology‐specific fusion genes, and potentially therapeutically targetable kinase fusions between the F1CDx and GenMineTOP.","confidence":0.6,"supports":true}
{"relationship_key":"prov:9034493c84e74bc1ae00f4f2650e6f25:associated_with:prov:68eec6a8055d46e7a1510da3fbae1f69","document_id":"PMC12775561_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"We compared the detection rates of oncogenic gene alterations, including SNV, indels, CNV, and gene fusions, as well as druggable gene alterations, histology‐specific fusion genes, and potentially therapeutically targetable kinase fusions between the F1CDx and GenMineTOP.","confidence":0.6,"supports":true}
{"relationship_key":"prov:68eec6a8055d46e7a1510da3fbae1f69:associated_with:prov:9034493c84e74bc1ae00f4f2650e6f25","document_id":"PMC12775561_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"We compared the detection rates of oncogenic gene alterations, including SNV, indels, CNV, and gene fusions, as well as druggable gene alterations, histology‐specific fusion genes, and potentially therapeutically targetable kinase fusions between the F1CDx and GenMineTOP.","confidence":0.6,"supports":true}
{"relationship_key":"prov:68eec6a8055d46e7a1510da3fbae1f69:associated_with:prov:9034493c84e74bc1ae00f4f2650e6f25","document_id":"PMC12775561_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"We compared the detection rates of oncogenic gene alterations, including SNV, indels, CNV, and gene fusions, as well as druggable gene alterations, histology‐specific fusion genes, and potentially therapeutically targetable kinase fusions between the F1CDx and GenMineTOP.","confidence":0.6,"supports":true}
{"relationship_key":"prov:5b6f9b44f63b4ebc9560014c4e2eba5b:manages:prov:85d150cfc3e44c0190b60f617e3737a2","document_id":"PMC12775561_window_15","section":null,"start_offset":0,"end_offset":0,"text_span":"based on the fusion genes BCOR::CCNB3, respectively.","confidence":0.9,"supports":true}
{"relationship_key":"prov:5b6f9b44f63b4ebc9560014c4e2eba5b:manages:prov:85d150cfc3e44c0190b60f617e3737a2","document_id":"PMC12775561_window_15","section":null,"start_offset":0,"end_offset":0,"text_span":"based on the fusion genes BCOR::CCNB3, respectively.","confidence":0.9,"supports":true}
{"relationship_key":"prov:85d150cfc3e44c0190b60f617e3737a2:diagnosed_by:prov:5b6f9b44f63b4ebc9560014c4e2eba5b","document_id":"PMC12775561_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"The identified fusion genes were visually represented in the Circos plot. (A) FoundationOne CDx cancer genome profiling.","confidence":0.8,"supports":true}
{"relationship_key":"prov:85d150cfc3e44c0190b60f617e3737a2:diagnosed_by:prov:5b6f9b44f63b4ebc9560014c4e2eba5b","document_id":"PMC12775561_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"The identified fusion genes were visually represented in the Circos plot. (A) FoundationOne CDx cancer genome profiling.","confidence":0.8,"supports":true}
{"relationship_key":"prov:85d150cfc3e44c0190b60f617e3737a2:associated_with:prov:68eec6a8055d46e7a1510da3fbae1f69","document_id":"PMC12775561_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"Potentially therapeutically targetable kinase fusions were found in 21 patients (2.0%).","confidence":0.8,"supports":true}
{"relationship_key":"prov:85d150cfc3e44c0190b60f617e3737a2:associated_with:prov:68eec6a8055d46e7a1510da3fbae1f69","document_id":"PMC12775561_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"Potentially therapeutically targetable kinase fusions were found in 21 patients (2.0%).","confidence":0.8,"supports":true}
{"relationship_key":"RxNorm:3639:treats:MeSH:D005354","document_id":"PMC12775561_window_27","section":null,"start_offset":0,"end_offset":0,"text_span":"fibrosarcoma is considered malignant and generally treated with doxorubicin","confidence":1.0,"supports":true}
{"relationship_key":"RxNorm:3639:treats:MeSH:D005354","document_id":"PMC12775561_window_27","section":null,"start_offset":0,"end_offset":0,"text_span":"fibrosarcoma is considered malignant and generally treated with doxorubicin","confidence":1.0,"supports":true}
{"relationship_key":"RxNorm:1148495:treats:prov:7fd5955259e241678bfea0f6a1a446f4","document_id":"PMC12775561_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"These include ALK inhibitors such as crizotinib and alectinib for ALK fusion‐positive sarcomas,","confidence":0.9,"supports":true}
{"relationship_key":"RxNorm:1148495:treats:prov:7fd5955259e241678bfea0f6a1a446f4","document_id":"PMC12775561_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"These include ALK inhibitors such as crizotinib and alectinib for ALK fusion‐positive sarcomas,","confidence":0.9,"supports":true}
{"relationship_key":"RxNorm:1727455:treats:prov:7fd5955259e241678bfea0f6a1a446f4","document_id":"PMC12775561_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"These include ALK inhibitors such as crizotinib and alectinib for ALK fusion‐positive sarcomas,","confidence":0.9,"supports":true}
{"relationship_key":"RxNorm:1727455:treats:prov:7fd5955259e241678bfea0f6a1a446f4","document_id":"PMC12775561_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"These include ALK inhibitors such as crizotinib and alectinib for ALK fusion‐positive sarcomas,","confidence":0.9,"supports":true}
{"relationship_key":"prov:68eec6a8055d46e7a1510da3fbae1f69:indicates:MeSH:D012515","document_id":"PMC12775561_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"Tyrosine kinase inhibitors (TKIs), for instance, have demonstrated strong efficacy in tumors harboring oncogenic fusion genes involving kinase activity","confidence":0.8,"supports":true}
{"relationship_key":"prov:68eec6a8055d46e7a1510da3fbae1f69:indicates:MeSH:D012515","document_id":"PMC12775561_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"Tyrosine kinase inhibitors (TKIs), for instance, have demonstrated strong efficacy in tumors harboring oncogenic fusion genes involving kinase activity","confidence":0.8,"supports":true}
{"relationship_key":"prov:7fd5955259e241678bfea0f6a1a446f4:associated_with:RxNorm:1148495","document_id":"PMC12775561_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"These include ALK inhibitors such as crizotinib and alectinib for ALK fusion‐positive sarcomas,","confidence":0.9,"supports":true}
{"relationship_key":"prov:7fd5955259e241678bfea0f6a1a446f4:associated_with:RxNorm:1148495","document_id":"PMC12775561_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"These include ALK inhibitors such as crizotinib and alectinib for ALK fusion‐positive sarcomas,","confidence":0.9,"supports":true}
{"relationship_key":"prov:367da93f77774281b5959b688c336269:decreases_risk:MeSH:D012515","document_id":"PMC12775561_window_30","section":null,"start_offset":0,"end_offset":0,"text_span":"The hereditary contribution to sarcoma has long been recognized, and several cancer predisposition genes have been implicated","confidence":0.9,"supports":true}
{"relationship_key":"prov:367da93f77774281b5959b688c336269:decreases_risk:MeSH:D012515","document_id":"PMC12775561_window_30","section":null,"start_offset":0,"end_offset":0,"text_span":"The hereditary contribution to sarcoma has long been recognized, and several cancer predisposition genes have been implicated","confidence":0.9,"supports":true}
{"relationship_key":"prov:367da93f77774281b5959b688c336269:indicates:prov:9c755ed79ffb4216a8efed78a988bacb","document_id":"PMC12775561_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"It is likely that some of these patients carried underlying hereditary cancer syndromes such as neurofibromatosis type 1 (NF1) or Li‐Fraumeni syndrome","confidence":0.7,"supports":true}
{"relationship_key":"prov:367da93f77774281b5959b688c336269:indicates:prov:9c755ed79ffb4216a8efed78a988bacb","document_id":"PMC12775561_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"It is likely that some of these patients carried underlying hereditary cancer syndromes such as neurofibromatosis type 1 (NF1) or Li‐Fraumeni syndrome","confidence":0.7,"supports":true}
{"relationship_key":"prov:367da93f77774281b5959b688c336269:indicates:MeSH:D016864","document_id":"PMC12775561_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"It is likely that some of these patients carried underlying hereditary cancer syndromes such as neurofibromatosis type 1 (NF1) or Li‐Fraumeni syndrome","confidence":0.7,"supports":true}
{"relationship_key":"prov:367da93f77774281b5959b688c336269:indicates:MeSH:D016864","document_id":"PMC12775561_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"It is likely that some of these patients carried underlying hereditary cancer syndromes such as neurofibromatosis type 1 (NF1) or Li‐Fraumeni syndrome","confidence":0.7,"supports":true}
{"relationship_key":"MeSH:D012515:diagnosed_by:prov:9367e8d197b64f44b3a73db35483a443","document_id":"PMC12775561_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Table S2: Comprehensive cancer genomic profiling tests.","confidence":1.0,"supports":true}
{"relationship_key":"MeSH:D012515:diagnosed_by:prov:9367e8d197b64f44b3a73db35483a443","document_id":"PMC12775561_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Table S2: Comprehensive cancer genomic profiling tests.","confidence":1.0,"supports":true}
{"relationship_key":"prov:f07136f160144000b1b08ce9c42f1b01:indicates:MeSH:D008654","document_id":"PMC12780394_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Pleural mesothelioma (PM) is an aggressive malignancy that originates on the mesothelial surface of the pleura, peritoneum, pericardium, and tunica vaginalis.","confidence":0.9,"supports":true}
{"relationship_key":"prov:f07136f160144000b1b08ce9c42f1b01:indicates:MeSH:D008654","document_id":"PMC12780394_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Pleural mesothelioma (PM) is an aggressive malignancy that originates on the mesothelial surface of the pleura, peritoneum, pericardium, and tunica vaginalis.","confidence":0.9,"supports":true}
{"relationship_key":"prov:f07136f160144000b1b08ce9c42f1b01:associated_with:MeSH:D008654","document_id":"PMC12780394_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"This study analyzed 662 publications on pleural mesothelioma (PM) biomarkers","confidence":1.0,"supports":true}
{"relationship_key":"prov:f07136f160144000b1b08ce9c42f1b01:associated_with:MeSH:D008654","document_id":"PMC12780394_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"This study analyzed 662 publications on pleural mesothelioma (PM) biomarkers","confidence":1.0,"supports":true}
{"relationship_key":"DBPedia:Asbestos:contraindicated_for:DBPedia:Malignancy","document_id":"PMC12780394_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"The predominant risk factor for PM is asbestos exposure, with approximately 80% of cases linked to prior asbestos contact (7).","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Asbestos:contraindicated_for:DBPedia:Malignancy","document_id":"PMC12780394_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"The predominant risk factor for PM is asbestos exposure, with approximately 80% of cases linked to prior asbestos contact (7).","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Asbestos:associated_with:DBPedia:Malignancy","document_id":"PMC12780394_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"The predominant risk factor for PM is asbestos exposure, with approximately 80% of cases linked to prior asbestos contact (7).","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Asbestos:associated_with:DBPedia:Malignancy","document_id":"PMC12780394_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"The predominant risk factor for PM is asbestos exposure, with approximately 80% of cases linked to prior asbestos contact (7).","confidence":0.9,"supports":true}
{"relationship_key":"prov:e1be6d51de314c5ba142cca88f581ea3:associated_with:prov:cf0d021461ec490ca1805d627c1adb51","document_id":"PMC12780394_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"This trend clearly underscores the increasing academic interest in mesothelioma biomarker research in recent years, establishing it as a prominent focal area within thoracic oncology.","confidence":0.9,"supports":true}
{"relationship_key":"prov:e1be6d51de314c5ba142cca88f581ea3:associated_with:prov:cf0d021461ec490ca1805d627c1adb51","document_id":"PMC12780394_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"This trend clearly underscores the increasing academic interest in mesothelioma biomarker research in recent years, establishing it as a prominent focal area within thoracic oncology.","confidence":0.9,"supports":true}
{"relationship_key":"prov:e1be6d51de314c5ba142cca88f581ea3:indicates:prov:f07136f160144000b1b08ce9c42f1b01","document_id":"PMC12780394_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"However, despite the growing attention paid to the research on mesothelioma biomarkers in the academic community at present, clinically useful PM biomarkers remain quite scarce.","confidence":0.8,"supports":true}
{"relationship_key":"prov:e1be6d51de314c5ba142cca88f581ea3:indicates:prov:f07136f160144000b1b08ce9c42f1b01","document_id":"PMC12780394_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"However, despite the growing attention paid to the research on mesothelioma biomarkers in the academic community at present, clinically useful PM biomarkers remain quite scarce.","confidence":0.8,"supports":true}
{"relationship_key":"prov:f07136f160144000b1b08ce9c42f1b01:associated_with:prov:e1be6d51de314c5ba142cca88f581ea3","document_id":"PMC12780394_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"However, despite the growing attention paid to the research on mesothelioma biomarkers in the academic community at present, clinically useful PM biomarkers remain quite scarce.","confidence":0.9,"supports":true}
{"relationship_key":"prov:f07136f160144000b1b08ce9c42f1b01:associated_with:prov:e1be6d51de314c5ba142cca88f581ea3","document_id":"PMC12780394_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"However, despite the growing attention paid to the research on mesothelioma biomarkers in the academic community at present, clinically useful PM biomarkers remain quite scarce.","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Asbestos:treats:MeSH:D008654","document_id":"PMC12780394_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"the high-frequency keywords were, in order, ... asbestos (n=56),","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Asbestos:treats:MeSH:D008654","document_id":"PMC12780394_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"the high-frequency keywords were, in order, ... asbestos (n=56),","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Asbestos:contraindicated_for:MeSH:D008654","document_id":"PMC12780394_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"the high-frequency keywords were, in order, ... asbestos (n=56),","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Asbestos:contraindicated_for:MeSH:D008654","document_id":"PMC12780394_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"the high-frequency keywords were, in order, ... asbestos (n=56),","confidence":0.7,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:indicates:MeSH:D008654","document_id":"PMC12780394_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"the high-frequency keywords were, in order, ... mesothelin (n=55),","confidence":0.6,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:indicates:MeSH:D008654","document_id":"PMC12780394_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"the high-frequency keywords were, in order, ... mesothelin (n=55),","confidence":0.6,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:associated_with:MeSH:D008654","document_id":"PMC12780394_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"the high-frequency keywords were, in order, ... mesothelin (n=55),","confidence":0.5,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:associated_with:MeSH:D008654","document_id":"PMC12780394_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"the high-frequency keywords were, in order, ... mesothelin (n=55),","confidence":0.5,"supports":true}
{"relationship_key":"DBPedia:Epigenetics:associated_with:prov:e1be6d51de314c5ba142cca88f581ea3","document_id":"PMC12780394_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"‘this clustering structure reflects the multidimensional nature of mesothelioma biomarker research’","confidence":0.6,"supports":true}
{"relationship_key":"DBPedia:Epigenetics:associated_with:prov:e1be6d51de314c5ba142cca88f581ea3","document_id":"PMC12780394_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"‘this clustering structure reflects the multidimensional nature of mesothelioma biomarker research’","confidence":0.6,"supports":true}
{"relationship_key":"MeSH:D008654:diagnosed_by:prov:b6f3b905f33b444e9595914122226e72","document_id":"PMC12780394_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"‘gauge gene expression’ in the context of ‘pleural mesothelioma’","confidence":0.7,"supports":true}
{"relationship_key":"MeSH:D008654:diagnosed_by:prov:b6f3b905f33b444e9595914122226e72","document_id":"PMC12780394_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"‘gauge gene expression’ in the context of ‘pleural mesothelioma’","confidence":0.7,"supports":true}
{"relationship_key":"RxNorm:1597876:treats:MeSH:D008654","document_id":"PMC12780394_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"Baas et al.’s article published in Lancet titled “First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial”","confidence":0.8,"supports":true}
{"relationship_key":"RxNorm:1597876:treats:MeSH:D008654","document_id":"PMC12780394_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"Baas et al.’s article published in Lancet titled “First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial”","confidence":0.8,"supports":true}
{"relationship_key":"RxNorm:1094833:treats:MeSH:D008654","document_id":"PMC12780394_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"Baas et al.’s article published in Lancet titled “First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial”","confidence":0.8,"supports":true}
{"relationship_key":"RxNorm:1094833:treats:MeSH:D008654","document_id":"PMC12780394_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"Baas et al.’s article published in Lancet titled “First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial”","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:associated_with:prov:df6c0153837c4986a3e94867e4b0f225","document_id":"PMC12780394_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"High-frequency keywords (top 20)RankKeywordsOccurrences1Mesothelioma1892Biomarkers1143Malignant pleural mesothelioma864Biomarker745Malignant mesothelioma656Asbestos567Mesothelin558Immunotherapy489Prognosis3810Diagnosis3311MicroRNA2712Immunohistochemistry2613Pleural mesothelioma2514Lung cancer2215Cancer2116Pleural effusion2117","confidence":0.6,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:associated_with:prov:df6c0153837c4986a3e94867e4b0f225","document_id":"PMC12780394_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"High-frequency keywords (top 20)RankKeywordsOccurrences1Mesothelioma1892Biomarkers1143Malignant pleural mesothelioma864Biomarker745Malignant mesothelioma656Asbestos567Mesothelin558Immunotherapy489Prognosis3810Diagnosis3311MicroRNA2712Immunohistochemistry2613Pleural mesothelioma2514Lung cancer2215Cancer2116Pleural effusion2117","confidence":0.6,"supports":true}
{"relationship_key":"MeSH:D008654:diagnosed_by:MeSH:D007150","document_id":"PMC12780394_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"High-frequency keywords (top 20)RankKeywordsOccurrences1Mesothelioma1892Biomarkers1143Malignant pleural mesothelioma864Biomarker745Malignant mesothelioma656Asbestos567Mesothelin558Immunotherapy489Prognosis3810Diagnosis3311MicroRNA2712Immunohistochemistry2613","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D008654:diagnosed_by:MeSH:D007150","document_id":"PMC12780394_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"High-frequency keywords (top 20)RankKeywordsOccurrences1Mesothelioma1892Biomarkers1143Malignant pleural mesothelioma864Biomarker745Malignant mesothelioma656Asbestos567Mesothelin558Immunotherapy489Prognosis3810Diagnosis3311MicroRNA2712Immunohistochemistry2613","confidence":0.9,"supports":true}
{"relationship_key":"RxNorm:1597876:interacts_with:RxNorm:1094833","document_id":"PMC12780394_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","confidence":0.8,"supports":true}
{"relationship_key":"RxNorm:1597876:interacts_with:RxNorm:1094833","document_id":"PMC12780394_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","confidence":0.8,"supports":true}
{"relationship_key":"prov:12d62dbdd40b4ec68e90d349d29a6cc5:indicates:MeSH:D008654","document_id":"PMC12780394_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"Evan W. Alley 434Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","confidence":0.8,"supports":true}
{"relationship_key":"prov:12d62dbdd40b4ec68e90d349d29a6cc5:indicates:MeSH:D008654","document_id":"PMC12780394_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"Evan W. Alley 434Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","confidence":0.8,"supports":true}
{"relationship_key":"prov:18a5acae8bb446789c5d465e07233d6d:treats:MeSH:D010190","document_id":"PMC12780394_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors","confidence":0.8,"supports":true}
{"relationship_key":"prov:18a5acae8bb446789c5d465e07233d6d:treats:MeSH:D010190","document_id":"PMC12780394_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors","confidence":0.8,"supports":true}
{"relationship_key":"prov:18a5acae8bb446789c5d465e07233d6d:treats:MeSH:D008654","document_id":"PMC12780394_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors","confidence":0.8,"supports":true}
{"relationship_key":"prov:18a5acae8bb446789c5d465e07233d6d:treats:MeSH:D008654","document_id":"PMC12780394_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:indicates:MeSH:D010190","document_id":"PMC12780394_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"As a diagnostic marker for ovarian cancer, pleural mesothelioma, pancreatic cancer and other tumors","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:indicates:MeSH:D010190","document_id":"PMC12780394_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"As a diagnostic marker for ovarian cancer, pleural mesothelioma, pancreatic cancer and other tumors","confidence":0.9,"supports":true}
{"relationship_key":"prov:e9f22ddd6b4e4ff0936a7b14fed68436:indicates:MeSH:D008654","document_id":"PMC12780394_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: correlation with survival","confidence":0.9,"supports":true}
{"relationship_key":"prov:e9f22ddd6b4e4ff0936a7b14fed68436:indicates:MeSH:D008654","document_id":"PMC12780394_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: correlation with survival","confidence":0.9,"supports":true}
{"relationship_key":"prov:8ed82c79c41a4eef930731aa5ffa49b8:indicates:MeSH:D008654","document_id":"PMC12780394_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"Deepen the research on the mechanism of predicting the efficacy of immunotherapy, especially in solid tumors such as mesothelioma","confidence":0.9,"supports":true}
{"relationship_key":"prov:8ed82c79c41a4eef930731aa5ffa49b8:indicates:MeSH:D008654","document_id":"PMC12780394_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"Deepen the research on the mechanism of predicting the efficacy of immunotherapy, especially in solid tumors such as mesothelioma","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Proteomics:associated_with:MeSH:D008654","document_id":"PMC12780394_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"is a high-throughput method of generating protein signatures, and has recently been used to efficiently screen for biomarkers and to improve the diagnostic accuracy of different cancers","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Proteomics:associated_with:MeSH:D008654","document_id":"PMC12780394_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"is a high-throughput method of generating protein signatures, and has recently been used to efficiently screen for biomarkers and to improve the diagnostic accuracy of different cancers","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:indicates:DBPedia:Malignancy","document_id":"PMC12780394_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers (21).","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:indicates:DBPedia:Malignancy","document_id":"PMC12780394_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers (21).","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:associated_with:MeSH:D010190","document_id":"PMC12780394_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers (21).","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:associated_with:MeSH:D010190","document_id":"PMC12780394_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers (21).","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:associated_with:DBPedia:Malignancy","document_id":"PMC12780394_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers (21).","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:A0A6J2HWX0:associated_with:DBPedia:Malignancy","document_id":"PMC12780394_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers (21).","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Asbestos:treats:prov:722c2e27bccb4272a7d89c795cb59522","document_id":"PMC12780394_window_33","section":null,"start_offset":0,"end_offset":0,"text_span":"Therefore, elevated levels of SMRP in the absence of renal disease should raise suspicion of malignancy.","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Asbestos:treats:prov:722c2e27bccb4272a7d89c795cb59522","document_id":"PMC12780394_window_33","section":null,"start_offset":0,"end_offset":0,"text_span":"Therefore, elevated levels of SMRP in the absence of renal disease should raise suspicion of malignancy.","confidence":0.8,"supports":true}
{"relationship_key":"prov:e06a2200a1d24b28a742949db5c1eec0:increases_risk:MeSH:D008545","document_id":"PMC12780394_window_35","section":null,"start_offset":0,"end_offset":0,"text_span":"miR-182-5p’s oncogenic function was first identified in melanoma, where the miRNA promotes tumor migration and invasion by inhibiting the activity of the forkhead box O3 (FOXO3) transcription factor (35).","confidence":1.0,"supports":true}
{"relationship_key":"prov:e06a2200a1d24b28a742949db5c1eec0:increases_risk:MeSH:D008545","document_id":"PMC12780394_window_35","section":null,"start_offset":0,"end_offset":0,"text_span":"miR-182-5p’s oncogenic function was first identified in melanoma, where the miRNA promotes tumor migration and invasion by inhibiting the activity of the forkhead box O3 (FOXO3) transcription factor (35).","confidence":1.0,"supports":true}
{"relationship_key":"prov:e06a2200a1d24b28a742949db5c1eec0:associated_with:MeSH:D008545","document_id":"PMC12780394_window_35","section":null,"start_offset":0,"end_offset":0,"text_span":"One of the tumorigenic miRNAs associated with PM development is miR-182-5p (34).","confidence":1.0,"supports":true}
{"relationship_key":"prov:e06a2200a1d24b28a742949db5c1eec0:associated_with:MeSH:D008545","document_id":"PMC12780394_window_35","section":null,"start_offset":0,"end_offset":0,"text_span":"One of the tumorigenic miRNAs associated with PM development is miR-182-5p (34).","confidence":1.0,"supports":true}
{"relationship_key":"HGNC:29859:indicates:MeSH:D008545","document_id":"PMC12780394_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"miRNAs encoded by the let-7 family were the first miRNAs identified to regulate the expression of the proto-oncogene RAS proteins, and current studies have demonstrated that the expression profiles of the let-7 miRNAs differed significantly between tumor cells and normal cells,","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:29859:indicates:MeSH:D008545","document_id":"PMC12780394_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"miRNAs encoded by the let-7 family were the first miRNAs identified to regulate the expression of the proto-oncogene RAS proteins, and current studies have demonstrated that the expression profiles of the let-7 miRNAs differed significantly between tumor cells and normal cells,","confidence":0.8,"supports":true}
{"relationship_key":"prov:e06a2200a1d24b28a742949db5c1eec0:affects:MeSH:D008545","document_id":"PMC12780394_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"miR-182-5p’s oncogenic function was first identified in melanoma, where the miRNA promotes tumor migration and invasion by inhibiting the activity of the forkhead box O3 (FOXO3) transcription factor","confidence":0.8,"supports":true}
{"relationship_key":"prov:e06a2200a1d24b28a742949db5c1eec0:affects:MeSH:D008545","document_id":"PMC12780394_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"miR-182-5p’s oncogenic function was first identified in melanoma, where the miRNA promotes tumor migration and invasion by inhibiting the activity of the forkhead box O3 (FOXO3) transcription factor","confidence":0.8,"supports":true}
{"relationship_key":"prov:05996ce0b01346e3856365614eac7c27:affects:MeSH:D008545","document_id":"PMC12780394_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"miR-182 and miR-183 is associated with the development of human malignant tumors","confidence":0.8,"supports":true}
{"relationship_key":"prov:05996ce0b01346e3856365614eac7c27:affects:MeSH:D008545","document_id":"PMC12780394_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"miR-182 and miR-183 is associated with the development of human malignant tumors","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:29859:associated_with:MeSH:D008545","document_id":"PMC12780394_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"miRNAs encoded by the let-7 family were the first miRNAs identified to regulate the expression of the proto-oncogene RAS proteins, and current studies have demonstrated that the expression profiles of the let-7 miRNAs differed significantly between tumor cells and normal cells,","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:29859:associated_with:MeSH:D008545","document_id":"PMC12780394_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"miRNAs encoded by the let-7 family were the first miRNAs identified to regulate the expression of the proto-oncogene RAS proteins, and current studies have demonstrated that the expression profiles of the let-7 miRNAs differed significantly between tumor cells and normal cells,","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Renal_cell_carcinoma:diagnosed_by:MeSH:D001706","document_id":"PMC12780394_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"DeRienzo et al. (43) used gene sequencing to sequentially and positively test 26 genes for the purpose of discriminating PM from other thoracic malignancies such as sarcomas, renal cell carcinomas,","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Renal_cell_carcinoma:diagnosed_by:MeSH:D001706","document_id":"PMC12780394_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"DeRienzo et al. (43) used gene sequencing to sequentially and positively test 26 genes for the purpose of discriminating PM from other thoracic malignancies such as sarcomas, renal cell carcinomas,","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Thymoma:diagnosed_by:MeSH:D001706","document_id":"PMC12780394_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"DeRienzo et al. (43) used gene sequencing to sequentially and positively test 26 genes for the purpose of discriminating PM from other thoracic malignancies such as sarcomas, renal cell carcinomas, and thymomas,","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Thymoma:diagnosed_by:MeSH:D001706","document_id":"PMC12780394_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"DeRienzo et al. (43) used gene sequencing to sequentially and positively test 26 genes for the purpose of discriminating PM from other thoracic malignancies such as sarcomas, renal cell carcinomas, and thymomas,","confidence":0.8,"supports":true}
{"relationship_key":"prov:f07136f160144000b1b08ce9c42f1b01:associated_with:prov:4b97eef12d9a4b84ae33550b4183ea93","document_id":"PMC12780394_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"Several different biomarkers were found to be effective in identifying patients with PM and benign chest diseases,","confidence":0.9,"supports":true}
{"relationship_key":"prov:f07136f160144000b1b08ce9c42f1b01:associated_with:prov:4b97eef12d9a4b84ae33550b4183ea93","document_id":"PMC12780394_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"Several different biomarkers were found to be effective in identifying patients with PM and benign chest diseases,","confidence":0.9,"supports":true}
{"relationship_key":"prov:f07136f160144000b1b08ce9c42f1b01:associated_with:DBPedia:Thymoma","document_id":"PMC12780394_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"Several different biomarkers were found to be effective in identifying patients with PM and benign chest diseases, different types of PM and other chest malignancies,","confidence":0.9,"supports":true}
{"relationship_key":"prov:f07136f160144000b1b08ce9c42f1b01:associated_with:DBPedia:Thymoma","document_id":"PMC12780394_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"Several different biomarkers were found to be effective in identifying patients with PM and benign chest diseases, different types of PM and other chest malignancies,","confidence":0.9,"supports":true}
{"relationship_key":"prov:4b97eef12d9a4b84ae33550b4183ea93:associated_with:prov:a04e324b13304923b15acb9b9b4f5288","document_id":"PMC12780394_window_39","section":null,"start_offset":0,"end_offset":0,"text_span":"Several different biomarkers were found to be effective in identifying patients with PM and benign chest diseases...","confidence":0.6,"supports":true}
{"relationship_key":"prov:4b97eef12d9a4b84ae33550b4183ea93:associated_with:prov:a04e324b13304923b15acb9b9b4f5288","document_id":"PMC12780394_window_39","section":null,"start_offset":0,"end_offset":0,"text_span":"Several different biomarkers were found to be effective in identifying patients with PM and benign chest diseases...","confidence":0.6,"supports":true}
{"relationship_key":"prov:df101f2435014f859cf8361a24a60d28:associated_with:prov:a04e324b13304923b15acb9b9b4f5288","document_id":"PMC12780394_window_39","section":null,"start_offset":0,"end_offset":0,"text_span":"Several different biomarkers were found to be effective in identifying patients with PM and benign chest diseases...","confidence":0.4,"supports":true}
{"relationship_key":"prov:df101f2435014f859cf8361a24a60d28:associated_with:prov:a04e324b13304923b15acb9b9b4f5288","document_id":"PMC12780394_window_39","section":null,"start_offset":0,"end_offset":0,"text_span":"Several different biomarkers were found to be effective in identifying patients with PM and benign chest diseases...","confidence":0.4,"supports":true}
{"relationship_key":"DBPedia:Benign_tumor:associated_with:prov:a04e324b13304923b15acb9b9b4f5288","document_id":"PMC12780394_window_39","section":null,"start_offset":0,"end_offset":0,"text_span":"Several different biomarkers were found to be effective in identifying patients with PM and benign chest diseases...","confidence":0.2,"supports":true}
{"relationship_key":"DBPedia:Benign_tumor:associated_with:prov:a04e324b13304923b15acb9b9b4f5288","document_id":"PMC12780394_window_39","section":null,"start_offset":0,"end_offset":0,"text_span":"Several different biomarkers were found to be effective in identifying patients with PM and benign chest diseases...","confidence":0.2,"supports":true}
{"relationship_key":"UniProt:P15941:indicates:prov:2ca5cba62e5a4059b8d166449a47e99b","document_id":"PMC12780394_window_43","section":null,"start_offset":0,"end_offset":0,"text_span":"One study also found elevated serum KL-6 levels in occupational asbestosis patients compared to healthy controls, suggesting KL-6 may serve as a biomarker for asbestos-related pulmonary injury.","confidence":0.7,"supports":true}
{"relationship_key":"UniProt:P15941:indicates:prov:2ca5cba62e5a4059b8d166449a47e99b","document_id":"PMC12780394_window_43","section":null,"start_offset":0,"end_offset":0,"text_span":"One study also found elevated serum KL-6 levels in occupational asbestosis patients compared to healthy controls, suggesting KL-6 may serve as a biomarker for asbestos-related pulmonary injury.","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Mutation:indicates:DBPedia:Chimpanzee","document_id":"PMC12783088_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Non-synonymous TSC2 mutations occurred in 80% of chimpanzees, versus ~7% in human HCC,","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Mutation:indicates:DBPedia:Chimpanzee","document_id":"PMC12783088_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Non-synonymous TSC2 mutations occurred in 80% of chimpanzees, versus ~7% in human HCC,","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:P35224:indicates:DBPedia:Chimpanzee","document_id":"PMC12783088_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"HCC and matched non-cancerous tissues from five chimpanzees were examined using histopathology, immunohistochemistry (β-catenin, ARID1A, TSC2, FAP, vimentin, TGF-β), whole-genome sequencing (one pair), and whole-exome sequencing (four pairs).","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:P35224:indicates:DBPedia:Chimpanzee","document_id":"PMC12783088_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"HCC and matched non-cancerous tissues from five chimpanzees were examined using histopathology, immunohistochemistry (β-catenin, ARID1A, TSC2, FAP, vimentin, TGF-β), whole-genome sequencing (one pair), and whole-exome sequencing (four pairs).","confidence":0.8,"supports":true}
{"relationship_key":"prov:6a0e9e0a65884f5e8fb30d16c2ad09d8:associated_with:DBPedia:Chimpanzee","document_id":"PMC12783088_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Chimpanzees (Pan troglodytes), sharing >98% genomic similarity with humans, display markedly different cancer spectra.","confidence":0.7,"supports":true}
{"relationship_key":"prov:6a0e9e0a65884f5e8fb30d16c2ad09d8:associated_with:DBPedia:Chimpanzee","document_id":"PMC12783088_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Chimpanzees (Pan troglodytes), sharing >98% genomic similarity with humans, display markedly different cancer spectra.","confidence":0.7,"supports":true}
{"relationship_key":"prov:146dd31871cf4c9fb8707cc5e5e537fe:associated_with:DBPedia:Chimpanzee","document_id":"PMC12783088_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Chimpanzees (Pan troglodytes), sharing >98% genomic similarity with humans, display markedly different cancer spectra.","confidence":0.7,"supports":true}
{"relationship_key":"prov:146dd31871cf4c9fb8707cc5e5e537fe:associated_with:DBPedia:Chimpanzee","document_id":"PMC12783088_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Chimpanzees (Pan troglodytes), sharing >98% genomic similarity with humans, display markedly different cancer spectra.","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Lung_cancer_susceptibility:associated_with:DBPedia:Chimpanzee","document_id":"PMC12783088_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Chimpanzees (Pan troglodytes), sharing >98% genomic similarity with humans, display markedly different cancer spectra.","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Lung_cancer_susceptibility:associated_with:DBPedia:Chimpanzee","document_id":"PMC12783088_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Chimpanzees (Pan troglodytes), sharing >98% genomic similarity with humans, display markedly different cancer spectra.","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Somatic_evolution_in_cancer:affects:DBPedia:Lifespan","document_id":"PMC12783088_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"despite widely variable life histories among mammalian species, including variation of around 30-fold in lifespan and around 40 000-fold in body mass, the somatic mutation load in non-cancerous tissues at the end of lifespan remained relatively constant","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Somatic_evolution_in_cancer:affects:DBPedia:Lifespan","document_id":"PMC12783088_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"despite widely variable life histories among mammalian species, including variation of around 30-fold in lifespan and around 40 000-fold in body mass, the somatic mutation load in non-cancerous tissues at the end of lifespan remained relatively constant","confidence":0.8,"supports":true}
{"relationship_key":"RxNorm:1427211:contraindicated_for:MeSH:D012550","document_id":"PMC12783088_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"Chronic viral hepatitis (Hepatitis B virus/HBV and Hepatitis C virus/HCV) remains a major cause of liver cancers in humans,","confidence":0.8,"supports":true}
{"relationship_key":"RxNorm:1427211:contraindicated_for:MeSH:D012550","document_id":"PMC12783088_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"Chronic viral hepatitis (Hepatitis B virus/HBV and Hepatitis C virus/HCV) remains a major cause of liver cancers in humans,","confidence":0.8,"supports":true}
{"relationship_key":"RxNorm:1427211:contraindicated_for:MeSH:D054298","document_id":"PMC12783088_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"Chronic viral hepatitis (Hepatitis B virus/HBV and Hepatitis C virus/HCV) remains a major cause of liver cancers in humans,","confidence":0.8,"supports":true}
{"relationship_key":"RxNorm:1427211:contraindicated_for:MeSH:D054298","document_id":"PMC12783088_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"Chronic viral hepatitis (Hepatitis B virus/HBV and Hepatitis C virus/HCV) remains a major cause of liver cancers in humans,","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D012550:associated_with:RxNorm:1427211","document_id":"PMC12783088_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"the relative prevalence of HCC among captive chimpanzees may be associated with their exposure to HBV and HCV infections, as well as Schistosoma mansoni and human immunodeficiency virus (HIV) co-infections","confidence":0.7,"supports":true}
{"relationship_key":"MeSH:D012550:associated_with:RxNorm:1427211","document_id":"PMC12783088_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"the relative prevalence of HCC among captive chimpanzees may be associated with their exposure to HBV and HCV infections, as well as Schistosoma mansoni and human immunodeficiency virus (HIV) co-infections","confidence":0.7,"supports":true}
{"relationship_key":"MeSH:D054298:associated_with:MeSH:D012550","document_id":"PMC12783088_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"the relative prevalence of HCC among captive chimpanzees may be associated with their exposure to HBV and HCV infections, as well as Schistosoma mansoni and human immunodeficiency virus (HIV) co-infections","confidence":0.7,"supports":true}
{"relationship_key":"MeSH:D054298:associated_with:MeSH:D012550","document_id":"PMC12783088_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"the relative prevalence of HCC among captive chimpanzees may be associated with their exposure to HBV and HCV infections, as well as Schistosoma mansoni and human immunodeficiency virus (HIV) co-infections","confidence":0.7,"supports":true}
{"relationship_key":"prov:63e93fb90a9f40d0aa18637dd8cd282c:diagnosed_by:prov:8a7d4530ebde42c7becc1788f7be9808","document_id":"PMC12783088_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"For WGS, TruSeq DNA libraries were prepared and sequenced on the HiSeq platform following Illumina’s protocols,","confidence":1.0,"supports":true}
{"relationship_key":"prov:63e93fb90a9f40d0aa18637dd8cd282c:diagnosed_by:prov:8a7d4530ebde42c7becc1788f7be9808","document_id":"PMC12783088_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"For WGS, TruSeq DNA libraries were prepared and sequenced on the HiSeq platform following Illumina’s protocols,","confidence":1.0,"supports":true}
{"relationship_key":"prov:63e93fb90a9f40d0aa18637dd8cd282c:diagnosed_by:prov:3a4b5210e0524376a395d358fbe33152","document_id":"PMC12783088_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"For WGS, TruSeq DNA libraries were prepared and sequenced on the HiSeq platform following Illumina’s protocols,","confidence":1.0,"supports":true}
{"relationship_key":"prov:63e93fb90a9f40d0aa18637dd8cd282c:diagnosed_by:prov:3a4b5210e0524376a395d358fbe33152","document_id":"PMC12783088_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"For WGS, TruSeq DNA libraries were prepared and sequenced on the HiSeq platform following Illumina’s protocols,","confidence":1.0,"supports":true}
{"relationship_key":"prov:63e93fb90a9f40d0aa18637dd8cd282c:diagnosed_by:prov:a2ddd872ac9d4274ac4a94bfc93f3b99","document_id":"PMC12783088_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"For WGS, TruSeq DNA libraries were prepared and sequenced on the HiSeq platform following Illumina’s protocols,","confidence":1.0,"supports":true}
{"relationship_key":"prov:63e93fb90a9f40d0aa18637dd8cd282c:diagnosed_by:prov:a2ddd872ac9d4274ac4a94bfc93f3b99","document_id":"PMC12783088_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"For WGS, TruSeq DNA libraries were prepared and sequenced on the HiSeq platform following Illumina’s protocols,","confidence":1.0,"supports":true}
{"relationship_key":"UniProt:P35224:indicates:prov:dd53e00100484c7cb591a5e9b8f85791","document_id":"PMC12783088_window_15","section":null,"start_offset":0,"end_offset":0,"text_span":"While normal human hepatocytes do not express β-catenin, it is expressed in HCC cells","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:P35224:indicates:prov:dd53e00100484c7cb591a5e9b8f85791","document_id":"PMC12783088_window_15","section":null,"start_offset":0,"end_offset":0,"text_span":"While normal human hepatocytes do not express β-catenin, it is expressed in HCC cells","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Somatic_evolution_in_cancer:indicates:DBPedia:Chimpanzee","document_id":"PMC12783088_window_18","section":null,"start_offset":0,"end_offset":0,"text_span":"Somatic mutation landscape in chimpanzee HCC","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Somatic_evolution_in_cancer:indicates:DBPedia:Chimpanzee","document_id":"PMC12783088_window_18","section":null,"start_offset":0,"end_offset":0,"text_span":"Somatic mutation landscape in chimpanzee HCC","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Frameshift_mutation:indicates:DBPedia:Chimpanzee","document_id":"PMC12783088_window_18","section":null,"start_offset":0,"end_offset":0,"text_span":"A total of 120 genes carrying at least one non-synonymous somatic mutation were found in all five chimpanzee HCC samples.","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Frameshift_mutation:indicates:DBPedia:Chimpanzee","document_id":"PMC12783088_window_18","section":null,"start_offset":0,"end_offset":0,"text_span":"A total of 120 genes carrying at least one non-synonymous somatic mutation were found in all five chimpanzee HCC samples.","confidence":0.8,"supports":true}
{"relationship_key":"prov:9b50f3155dd84c8c8f0ed059b6056b1f:associated_with:DBPedia:Mutation","document_id":"PMC12783088_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"Notably, this included TSC2 that was associated with the scirrhous subtype of HCC,","confidence":1.0,"supports":true}
{"relationship_key":"prov:9b50f3155dd84c8c8f0ed059b6056b1f:associated_with:DBPedia:Mutation","document_id":"PMC12783088_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"Notably, this included TSC2 that was associated with the scirrhous subtype of HCC,","confidence":1.0,"supports":true}
{"relationship_key":"DBPedia:Mutation:increases_risk:DBPedia:Somatic_evolution_in_cancer","document_id":"PMC12783088_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"Given the significance of TSC2 mutations in determining the HCC subtype,","confidence":1.0,"supports":true}
{"relationship_key":"DBPedia:Mutation:increases_risk:DBPedia:Somatic_evolution_in_cancer","document_id":"PMC12783088_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"Given the significance of TSC2 mutations in determining the HCC subtype,","confidence":1.0,"supports":true}
{"relationship_key":"prov:535b3d0df684459a8f4f3ae37fe3cd33:affects:DBPedia:Somatic_evolution_in_cancer","document_id":"PMC12783088_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"The substantial number of somatic mutations observed in chimpanzee HCC samples, particularly indels,","confidence":0.9,"supports":true}
{"relationship_key":"prov:535b3d0df684459a8f4f3ae37fe3cd33:affects:DBPedia:Somatic_evolution_in_cancer","document_id":"PMC12783088_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"The substantial number of somatic mutations observed in chimpanzee HCC samples, particularly indels,","confidence":0.9,"supports":true}
{"relationship_key":"prov:146dd31871cf4c9fb8707cc5e5e537fe:affects:DBPedia:Somatic_evolution_in_cancer","document_id":"PMC12783088_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"SNVs accounted for an average of 92.31% of all mutations in human datasets","confidence":0.9,"supports":true}
{"relationship_key":"prov:146dd31871cf4c9fb8707cc5e5e537fe:affects:DBPedia:Somatic_evolution_in_cancer","document_id":"PMC12783088_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"SNVs accounted for an average of 92.31% of all mutations in human datasets","confidence":0.9,"supports":true}
{"relationship_key":"prov:535b3d0df684459a8f4f3ae37fe3cd33:associated_with:DBPedia:Somatic_evolution_in_cancer","document_id":"PMC12783088_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"The substantial number of somatic mutations observed in chimpanzee HCC samples, particularly indels,","confidence":0.8,"supports":true}
{"relationship_key":"prov:535b3d0df684459a8f4f3ae37fe3cd33:associated_with:DBPedia:Somatic_evolution_in_cancer","document_id":"PMC12783088_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"The substantial number of somatic mutations observed in chimpanzee HCC samples, particularly indels,","confidence":0.8,"supports":true}
{"relationship_key":"prov:146dd31871cf4c9fb8707cc5e5e537fe:associated_with:DBPedia:Somatic_evolution_in_cancer","document_id":"PMC12783088_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"SNVs accounted for an average of 92.31% of all mutations in human datasets","confidence":0.8,"supports":true}
{"relationship_key":"prov:146dd31871cf4c9fb8707cc5e5e537fe:associated_with:DBPedia:Somatic_evolution_in_cancer","document_id":"PMC12783088_window_21","section":null,"start_offset":0,"end_offset":0,"text_span":"SNVs accounted for an average of 92.31% of all mutations in human datasets","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Mutation:indicates:DBPedia:Somatic_evolution_in_cancer","document_id":"PMC12783088_window_22","section":null,"start_offset":0,"end_offset":0,"text_span":"Eight non-synonymous somatic mutations were identified in TSC2 across chimpanzee HCC samples","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Mutation:indicates:DBPedia:Somatic_evolution_in_cancer","document_id":"PMC12783088_window_22","section":null,"start_offset":0,"end_offset":0,"text_span":"Eight non-synonymous somatic mutations were identified in TSC2 across chimpanzee HCC samples","confidence":0.7,"supports":true}
{"relationship_key":"UniProt:P35224:associated_with:DBPedia:Chimpanzee","document_id":"PMC12783088_window_28","section":null,"start_offset":0,"end_offset":0,"text_span":"Dysregulated Wnt/β-catenin signaling is implicated in ~40% of HCC cases [66].","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:P35224:associated_with:DBPedia:Chimpanzee","document_id":"PMC12783088_window_28","section":null,"start_offset":0,"end_offset":0,"text_span":"Dysregulated Wnt/β-catenin signaling is implicated in ~40% of HCC cases [66].","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Mutation:associated_with:prov:edc7312cd9814f918523c149e1dadfe5","document_id":"PMC12783088_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"The role of TSC2 and the mTOR signaling pathway in cancer progression is well-established in humans,","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Mutation:associated_with:prov:edc7312cd9814f918523c149e1dadfe5","document_id":"PMC12783088_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"The role of TSC2 and the mTOR signaling pathway in cancer progression is well-established in humans,","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Mutation:associated_with:prov:faa2544e5e8845e8a458180823c16005","document_id":"PMC12783088_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"The high frequency of these mutations in chimpanzee samples may indicate a parallel, yet distinct, evolutionary adaptation in this species.","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Mutation:associated_with:prov:faa2544e5e8845e8a458180823c16005","document_id":"PMC12783088_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"The high frequency of these mutations in chimpanzee samples may indicate a parallel, yet distinct, evolutionary adaptation in this species.","confidence":0.8,"supports":true}
{"relationship_key":"prov:dd53e00100484c7cb591a5e9b8f85791:affects:DBPedia:Mutation_Research_(journal)","document_id":"PMC12783088_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"the magnitude of the difference in mutation counts between chimpanzee and human HCCs","confidence":0.9,"supports":true}
{"relationship_key":"prov:dd53e00100484c7cb591a5e9b8f85791:affects:DBPedia:Mutation_Research_(journal)","document_id":"PMC12783088_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"the magnitude of the difference in mutation counts between chimpanzee and human HCCs","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Chimpanzee:affects:DBPedia:Mutation_Research_(journal)","document_id":"PMC12783088_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"the magnitude of the difference in mutation counts between chimpanzee and human HCCs","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Chimpanzee:affects:DBPedia:Mutation_Research_(journal)","document_id":"PMC12783088_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"the magnitude of the difference in mutation counts between chimpanzee and human HCCs","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D000077274:associated_with:HGNC:52649","document_id":"PMC12784210_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"BRD7 has been confirmed to be lowly expressed in nasopharyngeal carcinoma (NPC) tissues","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D000077274:associated_with:HGNC:52649","document_id":"PMC12784210_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"BRD7 has been confirmed to be lowly expressed in nasopharyngeal carcinoma (NPC) tissues","confidence":0.8,"supports":true}
{"relationship_key":"prov:8c1b85bb21b341108ab9e078001b0fa9:affects:prov:9079a555229b4f3fbcb287cfecbfe23b","document_id":"PMC12784210_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"This type of abnormal hypermethylation may result in transcriptional silencing, consequently facilitating tumourigenesis and progression.","confidence":0.9,"supports":true}
{"relationship_key":"prov:8c1b85bb21b341108ab9e078001b0fa9:affects:prov:9079a555229b4f3fbcb287cfecbfe23b","document_id":"PMC12784210_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"This type of abnormal hypermethylation may result in transcriptional silencing, consequently facilitating tumourigenesis and progression.","confidence":0.9,"supports":true}
{"relationship_key":"prov:8c1b85bb21b341108ab9e078001b0fa9:affects:MeSH:D001005","document_id":"PMC12784210_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"This type of abnormal hypermethylation may result in transcriptional silencing, consequently facilitating tumourigenesis and progression.","confidence":0.9,"supports":true}
{"relationship_key":"prov:8c1b85bb21b341108ab9e078001b0fa9:affects:MeSH:D001005","document_id":"PMC12784210_window_2","section":null,"start_offset":0,"end_offset":0,"text_span":"This type of abnormal hypermethylation may result in transcriptional silencing, consequently facilitating tumourigenesis and progression.","confidence":0.9,"supports":true}
{"relationship_key":"prov:ab575257154a41a9b53b8ff00435e99a:treats:prov:c67825f8d1294057a0ac08d92e6c2a48","document_id":"PMC12784210_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"effective in treating myelodysplastic syndromes (MDS)","confidence":0.9,"supports":true}
{"relationship_key":"prov:ab575257154a41a9b53b8ff00435e99a:treats:prov:c67825f8d1294057a0ac08d92e6c2a48","document_id":"PMC12784210_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"effective in treating myelodysplastic syndromes (MDS)","confidence":0.9,"supports":true}
{"relationship_key":"prov:2f0c14b43d1a4af0b2627e5bdae7629c:associated_with:prov:9079a555229b4f3fbcb287cfecbfe23b","document_id":"PMC12784210_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"facilitating tumourigenesis and progression","confidence":0.8,"supports":true}
{"relationship_key":"prov:2f0c14b43d1a4af0b2627e5bdae7629c:associated_with:prov:9079a555229b4f3fbcb287cfecbfe23b","document_id":"PMC12784210_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"facilitating tumourigenesis and progression","confidence":0.8,"supports":true}
{"relationship_key":"prov:8c1b85bb21b341108ab9e078001b0fa9:associated_with:prov:ee306ecea4f648bdbf4f653fec4b4e6f","document_id":"PMC12784210_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"leveraging the ease and specificity of the CRISPR/Cas9 system, which has been utilised for precise epigenomic modifications by linking to epigenomic regulatory elements.","confidence":0.7,"supports":true}
{"relationship_key":"prov:8c1b85bb21b341108ab9e078001b0fa9:associated_with:prov:ee306ecea4f648bdbf4f653fec4b4e6f","document_id":"PMC12784210_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"leveraging the ease and specificity of the CRISPR/Cas9 system, which has been utilised for precise epigenomic modifications by linking to epigenomic regulatory elements.","confidence":0.7,"supports":true}
{"relationship_key":"HGNC:52649:indicates:prov:4c22850cd2b242c9864f0aa5def5d694","document_id":"PMC12784210_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"a negative correlation with BRD7 expression and a positive correlation with clinical stage","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:52649:indicates:prov:4c22850cd2b242c9864f0aa5def5d694","document_id":"PMC12784210_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"a negative correlation with BRD7 expression and a positive correlation with clinical stage","confidence":0.9,"supports":true}
{"relationship_key":"prov:6dc2c80146ef4808a5e5a5071b4d48d5:treats:prov:4c22850cd2b242c9864f0aa5def5d694","document_id":"PMC12784210_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"ing BRD7 demethylation can effectively inhibit the malignant progression of NPC, thus offering a potential treatment strategy for NPC patients.","confidence":0.8,"supports":true}
{"relationship_key":"prov:6dc2c80146ef4808a5e5a5071b4d48d5:treats:prov:4c22850cd2b242c9864f0aa5def5d694","document_id":"PMC12784210_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"ing BRD7 demethylation can effectively inhibit the malignant progression of NPC, thus offering a potential treatment strategy for NPC patients.","confidence":0.8,"supports":true}
{"relationship_key":"prov:4c22850cd2b242c9864f0aa5def5d694:diagnosed_by:DBPedia:Western_blot","document_id":"PMC12784210_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"Immunohistochemistry was performed on cell blocks.","confidence":0.9,"supports":true}
{"relationship_key":"prov:4c22850cd2b242c9864f0aa5def5d694:diagnosed_by:DBPedia:Western_blot","document_id":"PMC12784210_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"Immunohistochemistry was performed on cell blocks.","confidence":0.9,"supports":true}
{"relationship_key":"prov:6dc2c80146ef4808a5e5a5071b4d48d5:interacts_with:prov:8464d85e2e374dc996ed8739eda76498","document_id":"PMC12784210_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"Reverse transcription was carried out to generate cDNA by using the reverse transcription kit","confidence":0.7,"supports":true}
{"relationship_key":"prov:6dc2c80146ef4808a5e5a5071b4d48d5:interacts_with:prov:8464d85e2e374dc996ed8739eda76498","document_id":"PMC12784210_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"Reverse transcription was carried out to generate cDNA by using the reverse transcription kit","confidence":0.7,"supports":true}
{"relationship_key":"prov:bca75f98ee344a1197d3afc0d505ebd7:associated_with:prov:2f0c14b43d1a4af0b2627e5bdae7629c","document_id":"PMC12784210_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"connected five sgRNAs specifically targeting the hypermethylated region of the CpG island of the BRD7 promoter","confidence":1.0,"supports":true}
{"relationship_key":"prov:bca75f98ee344a1197d3afc0d505ebd7:associated_with:prov:2f0c14b43d1a4af0b2627e5bdae7629c","document_id":"PMC12784210_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"connected five sgRNAs specifically targeting the hypermethylated region of the CpG island of the BRD7 promoter","confidence":1.0,"supports":true}
{"relationship_key":"DBPedia:Lentivirus:treats:MeSH:D001005","document_id":"PMC12784210_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"When the tumour volume reached 40–50 mm3, 100 µL of lentivirus stably expressing dCas9‐TET1CD‐sgRNA2, dCas9‐TET1CD‐sgRNA5 and combination of them with a concentration of 1 × 108 TU/mL were intratumourally injected,","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Lentivirus:treats:MeSH:D001005","document_id":"PMC12784210_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"When the tumour volume reached 40–50 mm3, 100 µL of lentivirus stably expressing dCas9‐TET1CD‐sgRNA2, dCas9‐TET1CD‐sgRNA5 and combination of them with a concentration of 1 × 108 TU/mL were intratumourally injected,","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:52649:indicates:MeSH:D000077274","document_id":"PMC12784210_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"RT‐PCR and Western blot analyses demonstrated that BRD7 expression in NPC patients samples was markedly lower than in non‐cancerous NP tissues","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:52649:indicates:MeSH:D000077274","document_id":"PMC12784210_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"RT‐PCR and Western blot analyses demonstrated that BRD7 expression in NPC patients samples was markedly lower than in non‐cancerous NP tissues","confidence":0.9,"supports":true}
{"relationship_key":"prov:2f0c14b43d1a4af0b2627e5bdae7629c:affects:MeSH:D000077274","document_id":"PMC12784210_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"hypermethylation of the BRD7 promoter mediates the downregulation of BRD7 expression in nasopharyngeal carcinoma (NPC)","confidence":0.9,"supports":true}
{"relationship_key":"prov:2f0c14b43d1a4af0b2627e5bdae7629c:affects:MeSH:D000077274","document_id":"PMC12784210_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"hypermethylation of the BRD7 promoter mediates the downregulation of BRD7 expression in nasopharyngeal carcinoma (NPC)","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:52649:decreases_risk:MeSH:D000077274","document_id":"PMC12784210_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"the downregulation of BRD7 expression in nasopharyngeal carcinoma (NPC)","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:52649:decreases_risk:MeSH:D000077274","document_id":"PMC12784210_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"the downregulation of BRD7 expression in nasopharyngeal carcinoma (NPC)","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:52649:encodes:UniProt:Q0PH31","document_id":"PMC12784210_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"DNMT, DNA methyltransferase.","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:52649:encodes:UniProt:Q0PH31","document_id":"PMC12784210_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"DNMT, DNA methyltransferase.","confidence":0.8,"supports":true}
{"relationship_key":"prov:bca75f98ee344a1197d3afc0d505ebd7:associated_with:prov:de7fbcab97fb42539393a467734e34d3","document_id":"PMC12784210_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"five specific sgRNAs targeting the hypermethylated areas of the CpG island within the BRD7 promoter were designed","confidence":0.9,"supports":true}
{"relationship_key":"prov:bca75f98ee344a1197d3afc0d505ebd7:associated_with:prov:de7fbcab97fb42539393a467734e34d3","document_id":"PMC12784210_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"five specific sgRNAs targeting the hypermethylated areas of the CpG island within the BRD7 promoter were designed","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:52649:located_in:prov:9bba6f5bb0b742deb981887c755e49f6","document_id":"PMC12784210_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"The LentiCRISPRv2/dCas9‐TET1CD‐sgRNAs system targets demethylation of BRD7 in NPC cells","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:52649:located_in:prov:9bba6f5bb0b742deb981887c755e49f6","document_id":"PMC12784210_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"The LentiCRISPRv2/dCas9‐TET1CD‐sgRNAs system targets demethylation of BRD7 in NPC cells","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:52649:associated_with:prov:9bba6f5bb0b742deb981887c755e49f6","document_id":"PMC12784210_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"The LentiCRISPRv2/dCas9‐TET1CD‐sgRNAs system targets demethylation of BRD7 in NPC cells","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:52649:associated_with:prov:9bba6f5bb0b742deb981887c755e49f6","document_id":"PMC12784210_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"The LentiCRISPRv2/dCas9‐TET1CD‐sgRNAs system targets demethylation of BRD7 in NPC cells","confidence":0.8,"supports":true}
{"relationship_key":"prov:de7fbcab97fb42539393a467734e34d3:associated_with:prov:bca75f98ee344a1197d3afc0d505ebd7","document_id":"PMC12784210_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"five specific sgRNAs targeting the hypermethylated areas of the CpG island within the BRD7 promoter were designed","confidence":0.9,"supports":true}
{"relationship_key":"prov:de7fbcab97fb42539393a467734e34d3:associated_with:prov:bca75f98ee344a1197d3afc0d505ebd7","document_id":"PMC12784210_window_20","section":null,"start_offset":0,"end_offset":0,"text_span":"five specific sgRNAs targeting the hypermethylated areas of the CpG island within the BRD7 promoter were designed","confidence":0.9,"supports":true}
{"relationship_key":"prov:2f0c14b43d1a4af0b2627e5bdae7629c:part_of:prov:bca75f98ee344a1197d3afc0d505ebd7","document_id":"PMC12784210_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"The qMSP experiment was conducted to assess the effects of the dCas9-TET1CD-sgRNAs demethylation system treatment on the methylation levels of the CpG island region in the BRD7 promoter","confidence":0.6,"supports":true}
{"relationship_key":"prov:2f0c14b43d1a4af0b2627e5bdae7629c:part_of:prov:bca75f98ee344a1197d3afc0d505ebd7","document_id":"PMC12784210_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"The qMSP experiment was conducted to assess the effects of the dCas9-TET1CD-sgRNAs demethylation system treatment on the methylation levels of the CpG island region in the BRD7 promoter","confidence":0.6,"supports":true}
{"relationship_key":"prov:b484bd5255ab4a2aa4fae8942abe2026:targets:HGNC:52649","document_id":"PMC12784210_window_30","section":null,"start_offset":0,"end_offset":0,"text_span":"transcriptionally activating BRD7 expression","confidence":0.8,"supports":true}
{"relationship_key":"prov:b484bd5255ab4a2aa4fae8942abe2026:targets:HGNC:52649","document_id":"PMC12784210_window_30","section":null,"start_offset":0,"end_offset":0,"text_span":"transcriptionally activating BRD7 expression","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D000077274:affects:HGNC:52649","document_id":"PMC12784210_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"Targeted demethylation of the BRD7 promoter inhibits the migration, invasion and EMT of nasopharyngeal carcinoma (NPC) cells.","confidence":1.0,"supports":true}
{"relationship_key":"MeSH:D000077274:affects:HGNC:52649","document_id":"PMC12784210_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"Targeted demethylation of the BRD7 promoter inhibits the migration, invasion and EMT of nasopharyngeal carcinoma (NPC) cells.","confidence":1.0,"supports":true}
{"relationship_key":"HGNC:52649:associated_with:MeSH:D000077274","document_id":"PMC12784210_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"Considering that dCas9‐TET1CD‐sgRNA2&sgRNA5 can suppress the proliferation, migration and invasion of NPC cells by transcriptionally activating BRD7,","confidence":1.0,"supports":true}
{"relationship_key":"HGNC:52649:associated_with:MeSH:D000077274","document_id":"PMC12784210_window_31","section":null,"start_offset":0,"end_offset":0,"text_span":"Considering that dCas9‐TET1CD‐sgRNA2&sgRNA5 can suppress the proliferation, migration and invasion of NPC cells by transcriptionally activating BRD7,","confidence":1.0,"supports":true}
{"relationship_key":"prov:2391b57171e4473f93c46a08cd8f63bc:affects:MeSH:D001005","document_id":"PMC12784210_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"the growth curve of the subcutaneous tumours indicated that stable expression of dCas9‐TET1CD‐sgRNA2 and dCas9‐TET1CD‐sgRNA5 markedly suppressed tumour growth in vivo","confidence":1.0,"supports":true}
{"relationship_key":"prov:2391b57171e4473f93c46a08cd8f63bc:affects:MeSH:D001005","document_id":"PMC12784210_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"the growth curve of the subcutaneous tumours indicated that stable expression of dCas9‐TET1CD‐sgRNA2 and dCas9‐TET1CD‐sgRNA5 markedly suppressed tumour growth in vivo","confidence":1.0,"supports":true}
{"relationship_key":"UniProt:A0A2D4P2D6:indicates:MeSH:D001005","document_id":"PMC12784210_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"immunohistochemical staining of BRD7, Ki67, CDK4, P21, Cleaved‐PARP, Vimentin and ZO‐1 in vivo tumours","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:A0A2D4P2D6:indicates:MeSH:D001005","document_id":"PMC12784210_window_36","section":null,"start_offset":0,"end_offset":0,"text_span":"immunohistochemical staining of BRD7, Ki67, CDK4, P21, Cleaved‐PARP, Vimentin and ZO‐1 in vivo tumours","confidence":0.8,"supports":true}
{"relationship_key":"prov:924fd906aacb4e5da844d6a8a2775abb:indicates:MeSH:D001005","document_id":"PMC12784210_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"the changes in tumour volume indicated that lentivirus with stable expression of LentiCRISPRv2/dCas9‐TET1CD‐sgRNA2&5 obviously inhibited tumour growth","confidence":1.0,"supports":true}
{"relationship_key":"prov:924fd906aacb4e5da844d6a8a2775abb:indicates:MeSH:D001005","document_id":"PMC12784210_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"the changes in tumour volume indicated that lentivirus with stable expression of LentiCRISPRv2/dCas9‐TET1CD‐sgRNA2&5 obviously inhibited tumour growth","confidence":1.0,"supports":true}
{"relationship_key":"MeSH:D001005:diagnosed_by:prov:c4b17fbbe19e42818abdf1f20e8b41b9","document_id":"PMC12784210_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Tumour tissues were extracted (Figure S7A)","confidence":1.0,"supports":true}
{"relationship_key":"MeSH:D001005:diagnosed_by:prov:c4b17fbbe19e42818abdf1f20e8b41b9","document_id":"PMC12784210_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Tumour tissues were extracted (Figure S7A)","confidence":1.0,"supports":true}
{"relationship_key":"prov:2391b57171e4473f93c46a08cd8f63bc:affects:prov:924fd906aacb4e5da844d6a8a2775abb","document_id":"PMC12784210_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"the changes in tumour volume indicated that lentivirus with stable expression of LentiCRISPRv2/dCas9‐TET1CD‐sgRNA2&5 obviously inhibited tumour growth","confidence":0.9,"supports":true}
{"relationship_key":"prov:2391b57171e4473f93c46a08cd8f63bc:affects:prov:924fd906aacb4e5da844d6a8a2775abb","document_id":"PMC12784210_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"the changes in tumour volume indicated that lentivirus with stable expression of LentiCRISPRv2/dCas9‐TET1CD‐sgRNA2&5 obviously inhibited tumour growth","confidence":0.9,"supports":true}
{"relationship_key":"prov:9864964747024ff796e52a14d3c60571:indicates:prov:924fd906aacb4e5da844d6a8a2775abb","document_id":"PMC12784210_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"the tumour volume and weight in the LV‐dCas9‐TET1CD‐sgRNA2 and sgRNA5 groups were significantly reduced, with tumour suppression rates of 68% and 79%, respectively","confidence":0.8,"supports":true}
{"relationship_key":"prov:9864964747024ff796e52a14d3c60571:indicates:prov:924fd906aacb4e5da844d6a8a2775abb","document_id":"PMC12784210_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"the tumour volume and weight in the LV‐dCas9‐TET1CD‐sgRNA2 and sgRNA5 groups were significantly reduced, with tumour suppression rates of 68% and 79%, respectively","confidence":0.8,"supports":true}
{"relationship_key":"prov:9864964747024ff796e52a14d3c60571:indicates:MeSH:D001005","document_id":"PMC12784210_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"the combination group demonstrated an even more dramatic tumour suppressive effect shown in Figure 9A","confidence":0.5,"supports":true}
{"relationship_key":"prov:9864964747024ff796e52a14d3c60571:indicates:MeSH:D001005","document_id":"PMC12784210_window_38","section":null,"start_offset":0,"end_offset":0,"text_span":"the combination group demonstrated an even more dramatic tumour suppressive effect shown in Figure 9A","confidence":0.5,"supports":true}
{"relationship_key":"prov:68d7d2aa44ac4e16815beb52625b67e0:treats:MeSH:D001005","document_id":"PMC12784210_window_41","section":null,"start_offset":0,"end_offset":0,"text_span":"can effectively infect tumours, leading to the demethylation of the highly methylated CpG island region","confidence":0.8,"supports":true}
{"relationship_key":"prov:68d7d2aa44ac4e16815beb52625b67e0:treats:MeSH:D001005","document_id":"PMC12784210_window_41","section":null,"start_offset":0,"end_offset":0,"text_span":"can effectively infect tumours, leading to the demethylation of the highly methylated CpG island region","confidence":0.8,"supports":true}
{"relationship_key":"prov:68d7d2aa44ac4e16815beb52625b67e0:associated_with:prov:2f0c14b43d1a4af0b2627e5bdae7629c","document_id":"PMC12784210_window_41","section":null,"start_offset":0,"end_offset":0,"text_span":"the demethylation of the highly methylated CpG island region of the BRD7 promoter","confidence":0.8,"supports":true}
{"relationship_key":"prov:68d7d2aa44ac4e16815beb52625b67e0:associated_with:prov:2f0c14b43d1a4af0b2627e5bdae7629c","document_id":"PMC12784210_window_41","section":null,"start_offset":0,"end_offset":0,"text_span":"the demethylation of the highly methylated CpG island region of the BRD7 promoter","confidence":0.8,"supports":true}
{"relationship_key":"prov:68d7d2aa44ac4e16815beb52625b67e0:associated_with:HGNC:52649","document_id":"PMC12784210_window_41","section":null,"start_offset":0,"end_offset":0,"text_span":"consequently activating BRD7 expression at the transcriptional level","confidence":0.8,"supports":true}
{"relationship_key":"prov:68d7d2aa44ac4e16815beb52625b67e0:associated_with:HGNC:52649","document_id":"PMC12784210_window_41","section":null,"start_offset":0,"end_offset":0,"text_span":"consequently activating BRD7 expression at the transcriptional level","confidence":0.8,"supports":true}
{"relationship_key":"prov:c923b0d119c54160a9b601de4b4eb3ba:indicates:MeSH:D001005","document_id":"PMC12784210_window_42","section":null,"start_offset":0,"end_offset":0,"text_span":"The blood parameters of the mice (including white blood cell and red blood cell counts, platelet counts and haemoglobin concentration) showed no marked changes","confidence":0.8,"supports":true}
{"relationship_key":"prov:c923b0d119c54160a9b601de4b4eb3ba:indicates:MeSH:D001005","document_id":"PMC12784210_window_42","section":null,"start_offset":0,"end_offset":0,"text_span":"The blood parameters of the mice (including white blood cell and red blood cell counts, platelet counts and haemoglobin concentration) showed no marked changes","confidence":0.8,"supports":true}
{"relationship_key":"prov:2f0c14b43d1a4af0b2627e5bdae7629c:associated_with:prov:bca75f98ee344a1197d3afc0d505ebd7","document_id":"PMC12784210_window_43","section":null,"start_offset":0,"end_offset":0,"text_span":"the methylation status of CpG island region of BRD7 promoter","confidence":0.8,"supports":true}
{"relationship_key":"prov:2f0c14b43d1a4af0b2627e5bdae7629c:associated_with:prov:bca75f98ee344a1197d3afc0d505ebd7","document_id":"PMC12784210_window_43","section":null,"start_offset":0,"end_offset":0,"text_span":"the methylation status of CpG island region of BRD7 promoter","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:52649:decreases_risk:prov:4c22850cd2b242c9864f0aa5def5d694","document_id":"PMC12784210_window_43","section":null,"start_offset":0,"end_offset":0,"text_span":"The results indicated that BRD7 expression was not significantly correlated with NPC patients age or gender","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:52649:decreases_risk:prov:4c22850cd2b242c9864f0aa5def5d694","document_id":"PMC12784210_window_43","section":null,"start_offset":0,"end_offset":0,"text_span":"The results indicated that BRD7 expression was not significantly correlated with NPC patients age or gender","confidence":0.8,"supports":true}
{"relationship_key":"prov:de7fbcab97fb42539393a467734e34d3:associated_with:MeSH:D000077274","document_id":"PMC12784210_window_44","section":null,"start_offset":0,"end_offset":0,"text_span":"The decreased expression of BRD7 is associated with the hypermethylation of the BRD7 promoter in biopsy tissues of nasopharyngeal carcinoma (NPC).","confidence":0.9,"supports":true}
{"relationship_key":"prov:de7fbcab97fb42539393a467734e34d3:associated_with:MeSH:D000077274","document_id":"PMC12784210_window_44","section":null,"start_offset":0,"end_offset":0,"text_span":"The decreased expression of BRD7 is associated with the hypermethylation of the BRD7 promoter in biopsy tissues of nasopharyngeal carcinoma (NPC).","confidence":0.9,"supports":true}
{"relationship_key":"prov:de7fbcab97fb42539393a467734e34d3:indicates:MeSH:D000077274","document_id":"PMC12784210_window_44","section":null,"start_offset":0,"end_offset":0,"text_span":"The decreased expression of BRD7 is associated with the hypermethylation of the BRD7 promoter in biopsy tissues of nasopharyngeal carcinoma (NPC).","confidence":0.9,"supports":true}
{"relationship_key":"prov:de7fbcab97fb42539393a467734e34d3:indicates:MeSH:D000077274","document_id":"PMC12784210_window_44","section":null,"start_offset":0,"end_offset":0,"text_span":"The decreased expression of BRD7 is associated with the hypermethylation of the BRD7 promoter in biopsy tissues of nasopharyngeal carcinoma (NPC).","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:52649:indicates:MeSH:D001005","document_id":"PMC12784210_window_48","section":null,"start_offset":0,"end_offset":0,"text_span":"targeting BRD7 demethylation can serve as an important molecular strategy for activating BRD7 and subsequent tumour treatment","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:52649:indicates:MeSH:D001005","document_id":"PMC12784210_window_48","section":null,"start_offset":0,"end_offset":0,"text_span":"targeting BRD7 demethylation can serve as an important molecular strategy for activating BRD7 and subsequent tumour treatment","confidence":0.9,"supports":true}
{"relationship_key":"prov:9bba6f5bb0b742deb981887c755e49f6:located_in:prov:645c21d2283e4282b8b3243a3db0e37a","document_id":"PMC12784210_window_50","section":null,"start_offset":0,"end_offset":0,"text_span":"constructed NPC cell lines stably transfected with dCas9‐TET1CD‐sgRNA2 and dCas9‐TET1CD‐sgRNA5","confidence":0.8,"supports":true}
{"relationship_key":"prov:9bba6f5bb0b742deb981887c755e49f6:located_in:prov:645c21d2283e4282b8b3243a3db0e37a","document_id":"PMC12784210_window_50","section":null,"start_offset":0,"end_offset":0,"text_span":"constructed NPC cell lines stably transfected with dCas9‐TET1CD‐sgRNA2 and dCas9‐TET1CD‐sgRNA5","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Lentivirus:interacts_with:DBPedia:Lentivirus","document_id":"PMC12784210_window_51","section":null,"start_offset":0,"end_offset":0,"text_span":"The demethylation system constructed in this study is a lentiviral vector, as lentiviruses possess strong transgenic delivery capabilities and can achieve long‐term stable expression in vivo.","confidence":0.5,"supports":true}
{"relationship_key":"DBPedia:Lentivirus:interacts_with:DBPedia:Lentivirus","document_id":"PMC12784210_window_51","section":null,"start_offset":0,"end_offset":0,"text_span":"The demethylation system constructed in this study is a lentiviral vector, as lentiviruses possess strong transgenic delivery capabilities and can achieve long‐term stable expression in vivo.","confidence":0.5,"supports":true}
{"relationship_key":"DBPedia:Lentivirus:treats:prov:9079a555229b4f3fbcb287cfecbfe23b","document_id":"PMC12784210_window_53","section":null,"start_offset":0,"end_offset":0,"text_span":"This indicates that the delivery of a lentivirus‐mediated demethylation system has potential applications in the future treatment of NPC.","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Lentivirus:treats:prov:9079a555229b4f3fbcb287cfecbfe23b","document_id":"PMC12784210_window_53","section":null,"start_offset":0,"end_offset":0,"text_span":"This indicates that the delivery of a lentivirus‐mediated demethylation system has potential applications in the future treatment of NPC.","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Adenoviridae:treats:prov:9079a555229b4f3fbcb287cfecbfe23b","document_id":"PMC12784210_window_53","section":null,"start_offset":0,"end_offset":0,"text_span":"This indicates that the delivery of a lentivirus‐mediated demethylation system has potential applications in the future treatment of NPC.","confidence":0.7,"supports":true}
{"relationship_key":"DBPedia:Adenoviridae:treats:prov:9079a555229b4f3fbcb287cfecbfe23b","document_id":"PMC12784210_window_53","section":null,"start_offset":0,"end_offset":0,"text_span":"This indicates that the delivery of a lentivirus‐mediated demethylation system has potential applications in the future treatment of NPC.","confidence":0.7,"supports":true}
{"relationship_key":"MeSH:D001005:causes:prov:2391b57171e4473f93c46a08cd8f63bc","document_id":"PMC12784210_window_55","section":null,"start_offset":0,"end_offset":0,"text_span":"inhibits tumour progression","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D001005:causes:prov:2391b57171e4473f93c46a08cd8f63bc","document_id":"PMC12784210_window_55","section":null,"start_offset":0,"end_offset":0,"text_span":"inhibits tumour progression","confidence":0.9,"supports":true}
{"relationship_key":"prov:8c1b85bb21b341108ab9e078001b0fa9:associated_with:HGNC:52649","document_id":"PMC12784210_window_56","section":null,"start_offset":0,"end_offset":0,"text_span":"there are hypermethylation modifications in the CpG island region of BRD7 promoter, which were negatively correlated with BRD7 expression","confidence":0.9,"supports":true}
{"relationship_key":"prov:8c1b85bb21b341108ab9e078001b0fa9:associated_with:HGNC:52649","document_id":"PMC12784210_window_56","section":null,"start_offset":0,"end_offset":0,"text_span":"there are hypermethylation modifications in the CpG island region of BRD7 promoter, which were negatively correlated with BRD7 expression","confidence":0.9,"supports":true}
{"relationship_key":"prov:86b36be917014e8ea2fbd2b18f5544c5:causes:prov:2391b57171e4473f93c46a08cd8f63bc","document_id":"PMC12784210_window_56","section":null,"start_offset":0,"end_offset":0,"text_span":"can inhibit the proliferation, migration, invasion and tumour growth in vivo of NPC cells","confidence":0.8,"supports":true}
{"relationship_key":"prov:86b36be917014e8ea2fbd2b18f5544c5:causes:prov:2391b57171e4473f93c46a08cd8f63bc","document_id":"PMC12784210_window_56","section":null,"start_offset":0,"end_offset":0,"text_span":"can inhibit the proliferation, migration, invasion and tumour growth in vivo of NPC cells","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:52649:decreases_risk:prov:86b36be917014e8ea2fbd2b18f5544c5","document_id":"PMC12784210_window_56","section":null,"start_offset":0,"end_offset":0,"text_span":"can activate BRD7 expression to varying degrees and inhibit the proliferation of tumour cells","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:52649:decreases_risk:prov:86b36be917014e8ea2fbd2b18f5544c5","document_id":"PMC12784210_window_56","section":null,"start_offset":0,"end_offset":0,"text_span":"can activate BRD7 expression to varying degrees and inhibit the proliferation of tumour cells","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:14583:indicates:prov:6120eb2f5d9c4df4adc88c8f396ba66e","document_id":"PMC12784249_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"We analyzed tumor suppressors in cancer cell lines and identified lethal gene knock-in strategies.","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:14583:indicates:prov:6120eb2f5d9c4df4adc88c8f396ba66e","document_id":"PMC12784249_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"We analyzed tumor suppressors in cancer cell lines and identified lethal gene knock-in strategies.","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:55980:increases_risk:prov:6120eb2f5d9c4df4adc88c8f396ba66e","document_id":"PMC12784249_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"We applied the concept of synthetic dosage lethality to predict essential genes in cancer and demonstrated a significant increase in sensitivity when compared to large-scale gene knockout screen data.","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:55980:increases_risk:prov:6120eb2f5d9c4df4adc88c8f396ba66e","document_id":"PMC12784249_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"We applied the concept of synthetic dosage lethality to predict essential genes in cancer and demonstrated a significant increase in sensitivity when compared to large-scale gene knockout screen data.","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Synthetic_lethality:affects:prov:6120eb2f5d9c4df4adc88c8f396ba66e","document_id":"PMC12784249_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"This strategy has driven the development of sophisticated targeted therapies in cancer, such as PARP inhibitors for patients with BRCA1- or BRCA2-mutated breast cancer","confidence":0.8,"supports":true}
{"relationship_key":"DBPedia:Synthetic_lethality:affects:prov:6120eb2f5d9c4df4adc88c8f396ba66e","document_id":"PMC12784249_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"This strategy has driven the development of sophisticated targeted therapies in cancer, such as PARP inhibitors for patients with BRCA1- or BRCA2-mutated breast cancer","confidence":0.8,"supports":true}
{"relationship_key":"prov:6120eb2f5d9c4df4adc88c8f396ba66e:associated_with:prov:22d0ad4356634e8ca4afffd7a100dcf4","document_id":"PMC12784249_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"illustrate the ability of our gMIS approach to elucidate potential targets for cancer research with several examples in hematological malignancies.","confidence":0.9,"supports":true}
{"relationship_key":"prov:6120eb2f5d9c4df4adc88c8f396ba66e:associated_with:prov:22d0ad4356634e8ca4afffd7a100dcf4","document_id":"PMC12784249_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"illustrate the ability of our gMIS approach to elucidate potential targets for cancer research with several examples in hematological malignancies.","confidence":0.9,"supports":true}
{"relationship_key":"prov:6120eb2f5d9c4df4adc88c8f396ba66e:diagnosed_by:prov:842ed660ffb445bf806b1a51dc6574d9","document_id":"PMC12784249_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"conducted a tumor suppressor analysis in cancer cell lines","confidence":0.8,"supports":true}
{"relationship_key":"prov:6120eb2f5d9c4df4adc88c8f396ba66e:diagnosed_by:prov:842ed660ffb445bf806b1a51dc6574d9","document_id":"PMC12784249_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"conducted a tumor suppressor analysis in cancer cell lines","confidence":0.8,"supports":true}
{"relationship_key":"prov:57e10158a5d34e65abb1319fc295d134:associated_with:HGNC:55980","document_id":"PMC12784249_window_25","section":null,"start_offset":0,"end_offset":0,"text_span":"The predicted essential genes with DepMap essentiality scores (Meyers et al. 2017)","confidence":1.0,"supports":true}
{"relationship_key":"prov:57e10158a5d34e65abb1319fc295d134:associated_with:HGNC:55980","document_id":"PMC12784249_window_25","section":null,"start_offset":0,"end_offset":0,"text_span":"The predicted essential genes with DepMap essentiality scores (Meyers et al. 2017)","confidence":1.0,"supports":true}
{"relationship_key":"prov:d3552bd9a6654936841e10859f70b3da:targets:HGNC:55980","document_id":"PMC12784249_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"We expand on our previous gMCS formulation to compute genetic Minimal Intervention Sets (gMISs),","confidence":0.6,"supports":true}
{"relationship_key":"prov:d3552bd9a6654936841e10859f70b3da:targets:HGNC:55980","document_id":"PMC12784249_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"We expand on our previous gMCS formulation to compute genetic Minimal Intervention Sets (gMISs),","confidence":0.6,"supports":true}
{"relationship_key":"prov:b43f083a8069468794cb785adde326c6:associated_with:prov:bc2cc108ba844edaa949a35039170c3c","document_id":"PMC12784249_window_35","section":null,"start_offset":0,"end_offset":0,"text_span":"The computational and functional biological analysis presented here demonstrates that gMIS approach can be effectively utilized to investigate the regulation of cancer metabolism","confidence":1.0,"supports":true}
{"relationship_key":"prov:b43f083a8069468794cb785adde326c6:associated_with:prov:bc2cc108ba844edaa949a35039170c3c","document_id":"PMC12784249_window_35","section":null,"start_offset":0,"end_offset":0,"text_span":"The computational and functional biological analysis presented here demonstrates that gMIS approach can be effectively utilized to investigate the regulation of cancer metabolism","confidence":1.0,"supports":true}
{"relationship_key":"MeSH:D000079403:indicates:MeSH:D016923","document_id":"PMC12784773_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Cells undergoing ferroptosis appear to have a reduced cell volume, with a characteristic loss of membrane integrity [5].","confidence":0.5,"supports":true}
{"relationship_key":"MeSH:D000079403:indicates:MeSH:D016923","document_id":"PMC12784773_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Cells undergoing ferroptosis appear to have a reduced cell volume, with a characteristic loss of membrane integrity [5].","confidence":0.5,"supports":true}
{"relationship_key":"MeSH:D000069292:subtype_of:MeSH:D016923","document_id":"PMC12784773_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"This form of cell death is considered to be distinct from other forms, such as apoptosis, pyroptosis, and necroptosis, in both morphological and mechanistic ways [2].","confidence":0.4,"supports":true}
{"relationship_key":"MeSH:D000069292:subtype_of:MeSH:D016923","document_id":"PMC12784773_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"This form of cell death is considered to be distinct from other forms, such as apoptosis, pyroptosis, and necroptosis, in both morphological and mechanistic ways [2].","confidence":0.4,"supports":true}
{"relationship_key":"MeSH:D000079302:subtype_of:MeSH:D016923","document_id":"PMC12784773_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"This form of cell death is considered to be distinct from other forms, such as apoptosis, pyroptosis, and necroptosis, in both morphological and mechanistic ways [2].","confidence":0.4,"supports":true}
{"relationship_key":"MeSH:D000079302:subtype_of:MeSH:D016923","document_id":"PMC12784773_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"This form of cell death is considered to be distinct from other forms, such as apoptosis, pyroptosis, and necroptosis, in both morphological and mechanistic ways [2].","confidence":0.4,"supports":true}
{"relationship_key":"MeSH:D016923:subtype_of:MeSH:D000079403","document_id":"PMC12784773_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Ferroptosis is an iron-dependent form of programmed cell death that is driven by the accumulation of reactive oxygen species (ROS), leading to the formation of membrane-damaging lipid peroxides [1].","confidence":0.3,"supports":true}
{"relationship_key":"MeSH:D016923:subtype_of:MeSH:D000079403","document_id":"PMC12784773_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Ferroptosis is an iron-dependent form of programmed cell death that is driven by the accumulation of reactive oxygen species (ROS), leading to the formation of membrane-damaging lipid peroxides [1].","confidence":0.3,"supports":true}
{"relationship_key":"MeSH:D000079403:diagnosed_by:prov:c6bdfd2c6c10498383313a6c2ee38e87","document_id":"PMC12784773_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"Importantly, they were able to identify that ferroptosis could not be suppressed by inhibitors of caspases or necroptosis; thus, this form of cell death is executed by lipid peroxidation and iron metabolism [8].","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D000079403:diagnosed_by:prov:c6bdfd2c6c10498383313a6c2ee38e87","document_id":"PMC12784773_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"Importantly, they were able to identify that ferroptosis could not be suppressed by inhibitors of caspases or necroptosis; thus, this form of cell death is executed by lipid peroxidation and iron metabolism [8].","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D000079403:diagnosed_by:prov:200612fe619141c6bab1eb3c928ee682","document_id":"PMC12784773_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"Yang et al. followed up on this work and further proved that the mechanism of ferroptosis is based on lipid peroxidation and not just general ROS production [9].","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D000079403:diagnosed_by:prov:200612fe619141c6bab1eb3c928ee682","document_id":"PMC12784773_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"Yang et al. followed up on this work and further proved that the mechanism of ferroptosis is based on lipid peroxidation and not just general ROS production [9].","confidence":0.9,"supports":true}
{"relationship_key":"prov:6c8c3e8198044ae09e3f4e3214a9bc69:indicates:DBPedia:Triple-negative_breast_cancer","document_id":"PMC12784773_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"Ferroptotic cell death has been found to be particularly important for cancers that display dysregulations in iron metabolism, lipid remodeling, and redox imbalances.","confidence":0.9,"supports":true}
{"relationship_key":"prov:6c8c3e8198044ae09e3f4e3214a9bc69:indicates:DBPedia:Triple-negative_breast_cancer","document_id":"PMC12784773_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"Ferroptotic cell death has been found to be particularly important for cancers that display dysregulations in iron metabolism, lipid remodeling, and redox imbalances.","confidence":0.9,"supports":true}
{"relationship_key":"prov:6c8c3e8198044ae09e3f4e3214a9bc69:indicates:MeSH:D016923","document_id":"PMC12784773_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"Ferroptotic cell death has been found to be particularly important for cancers that display dysregulations in iron metabolism, lipid remodeling, and redox imbalances.","confidence":0.9,"supports":true}
{"relationship_key":"prov:6c8c3e8198044ae09e3f4e3214a9bc69:indicates:MeSH:D016923","document_id":"PMC12784773_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"Ferroptotic cell death has been found to be particularly important for cancers that display dysregulations in iron metabolism, lipid remodeling, and redox imbalances.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D000079403:diagnosed_by:DBPedia:Fenton's_reagent","document_id":"PMC12784773_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"Iron in its ferrous state (Fe2+) is required for the Fenton reaction, a chemical process in which ferrous iron ions are used in the decomposition of hydrogen peroxide (H2O2) to create reactive hydroxyl radicals [19];","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D000079403:diagnosed_by:DBPedia:Fenton's_reagent","document_id":"PMC12784773_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"Iron in its ferrous state (Fe2+) is required for the Fenton reaction, a chemical process in which ferrous iron ions are used in the decomposition of hydrogen peroxide (H2O2) to create reactive hydroxyl radicals [19];","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D000079403:indicates:UniProt:P07798","document_id":"PMC12784773_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"Nuclear Receptor Coactivator 4 (NCOA4) is a protein that promotes ferritin degradation, also contributing to the labile iron pool [22].","confidence":0.7,"supports":true}
{"relationship_key":"MeSH:D000079403:indicates:UniProt:P07798","document_id":"PMC12784773_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"Nuclear Receptor Coactivator 4 (NCOA4) is a protein that promotes ferritin degradation, also contributing to the labile iron pool [22].","confidence":0.7,"supports":true}
{"relationship_key":"MeSH:D000079403:associated_with:UniProt:P07798","document_id":"PMC12784773_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"Nuclear Receptor Coactivator 4 (NCOA4) is a protein that promotes ferritin degradation, also contributing to the labile iron pool [22].","confidence":0.6,"supports":true}
{"relationship_key":"MeSH:D000079403:associated_with:UniProt:P07798","document_id":"PMC12784773_window_4","section":null,"start_offset":0,"end_offset":0,"text_span":"Nuclear Receptor Coactivator 4 (NCOA4) is a protein that promotes ferritin degradation, also contributing to the labile iron pool [22].","confidence":0.6,"supports":true}
{"relationship_key":"prov:c6bdfd2c6c10498383313a6c2ee38e87:affects:prov:6c8c3e8198044ae09e3f4e3214a9bc69","document_id":"PMC12784773_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"The lipid peroxidation that occurs greatly reduces membrane integrity, leading to eventual ferroptotic cell death [24].","confidence":1.0,"supports":true}
{"relationship_key":"prov:c6bdfd2c6c10498383313a6c2ee38e87:affects:prov:6c8c3e8198044ae09e3f4e3214a9bc69","document_id":"PMC12784773_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"The lipid peroxidation that occurs greatly reduces membrane integrity, leading to eventual ferroptotic cell death [24].","confidence":1.0,"supports":true}
{"relationship_key":"MeSH:D016923:diagnosed_by:DBPedia:Fenton's_reagent","document_id":"PMC12784773_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"The reactive oxygen species (ROS) produced in the Fenton reaction contribute greatly to the overwhelming of the cell’s antioxidant defenses, leading to lipid peroxidation and eventual cell death [23].","confidence":1.0,"supports":true}
{"relationship_key":"MeSH:D016923:diagnosed_by:DBPedia:Fenton's_reagent","document_id":"PMC12784773_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"The reactive oxygen species (ROS) produced in the Fenton reaction contribute greatly to the overwhelming of the cell’s antioxidant defenses, leading to lipid peroxidation and eventual cell death [23].","confidence":1.0,"supports":true}
{"relationship_key":"prov:c6bdfd2c6c10498383313a6c2ee38e87:indicates:MeSH:D016923","document_id":"PMC12784773_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"The reactive oxygen species (ROS) produced in the Fenton reaction contribute greatly to the overwhelming of the cell’s antioxidant defenses, leading to lipid peroxidation and eventual cell death [23].","confidence":1.0,"supports":true}
{"relationship_key":"prov:c6bdfd2c6c10498383313a6c2ee38e87:indicates:MeSH:D016923","document_id":"PMC12784773_window_5","section":null,"start_offset":0,"end_offset":0,"text_span":"The reactive oxygen species (ROS) produced in the Fenton reaction contribute greatly to the overwhelming of the cell’s antioxidant defenses, leading to lipid peroxidation and eventual cell death [23].","confidence":1.0,"supports":true}
{"relationship_key":"UniProt:P07798:indicates:MeSH:D000079403","document_id":"PMC12784773_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"Iron chelators can bind to and reduce the iron levels in the cell, and ferritin, an iron storage protein, can also contribute to the regulation of intracellular iron levels, preventing ferroptosis [29].","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:P07798:indicates:MeSH:D000079403","document_id":"PMC12784773_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"Iron chelators can bind to and reduce the iron levels in the cell, and ferritin, an iron storage protein, can also contribute to the regulation of intracellular iron levels, preventing ferroptosis [29].","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:P07798:associated_with:MeSH:D000079403","document_id":"PMC12784773_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"Iron chelators can bind to and reduce the iron levels in the cell, and ferritin, an iron storage protein, can also contribute to the regulation of intracellular iron levels, preventing ferroptosis [29].","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:P07798:associated_with:MeSH:D000079403","document_id":"PMC12784773_window_7","section":null,"start_offset":0,"end_offset":0,"text_span":"Iron chelators can bind to and reduce the iron levels in the cell, and ferritin, an iron storage protein, can also contribute to the regulation of intracellular iron levels, preventing ferroptosis [29].","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:H0Y8E8:associated_with:MeSH:D000079403","document_id":"PMC12784773_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"Other tumor-suppressor proteins, BRCA1-associated protein-1 (BAP1) and APC membrane recruitment protein 1 (AMER1), can also contribute to ferroptosis modulation","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:H0Y8E8:associated_with:MeSH:D000079403","document_id":"PMC12784773_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"Other tumor-suppressor proteins, BRCA1-associated protein-1 (BAP1) and APC membrane recruitment protein 1 (AMER1), can also contribute to ferroptosis modulation","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:A0A8C4X9Z9:associated_with:MeSH:D000079403","document_id":"PMC12784773_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"Other tumor-suppressor proteins, BRCA1-associated protein-1 (BAP1) and APC membrane recruitment protein 1 (AMER1), can also contribute to ferroptosis modulation","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:A0A8C4X9Z9:associated_with:MeSH:D000079403","document_id":"PMC12784773_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"Other tumor-suppressor proteins, BRCA1-associated protein-1 (BAP1) and APC membrane recruitment protein 1 (AMER1), can also contribute to ferroptosis modulation","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:Q14145:associated_with:MeSH:D000079403","document_id":"PMC12784773_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is controlled by tumor suppressors kelch-like ECH-associated protein 1 (KEAP1) and alternative reading frame (ARF)","confidence":0.8,"supports":true}
{"relationship_key":"UniProt:Q14145:associated_with:MeSH:D000079403","document_id":"PMC12784773_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is controlled by tumor suppressors kelch-like ECH-associated protein 1 (KEAP1) and alternative reading frame (ARF)","confidence":0.8,"supports":true}
{"relationship_key":"prov:8e8f29c9228f4bbb96b2a6e989072446:associated_with:MeSH:D000079403","document_id":"PMC12784773_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is controlled by tumor suppressors kelch-like ECH-associated protein 1 (KEAP1) and alternative reading frame (ARF)","confidence":0.8,"supports":true}
{"relationship_key":"prov:8e8f29c9228f4bbb96b2a6e989072446:associated_with:MeSH:D000079403","document_id":"PMC12784773_window_8","section":null,"start_offset":0,"end_offset":0,"text_span":"Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is controlled by tumor suppressors kelch-like ECH-associated protein 1 (KEAP1) and alternative reading frame (ARF)","confidence":0.8,"supports":true}
{"relationship_key":"prov:c6bdfd2c6c10498383313a6c2ee38e87:indicates:prov:6c8c3e8198044ae09e3f4e3214a9bc69","document_id":"PMC12784773_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"sensitizes cells to lipid peroxidation and thus ferroptotic cell death","confidence":0.9,"supports":true}
{"relationship_key":"prov:c6bdfd2c6c10498383313a6c2ee38e87:indicates:prov:6c8c3e8198044ae09e3f4e3214a9bc69","document_id":"PMC12784773_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"sensitizes cells to lipid peroxidation and thus ferroptotic cell death","confidence":0.9,"supports":true}
{"relationship_key":"prov:200612fe619141c6bab1eb3c928ee682:indicates:MeSH:D000079403","document_id":"PMC12784773_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"Tumor cells evade ferroptosis by lowering mitochondrial ROS production","confidence":0.8,"supports":true}
{"relationship_key":"prov:200612fe619141c6bab1eb3c928ee682:indicates:MeSH:D000079403","document_id":"PMC12784773_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"Tumor cells evade ferroptosis by lowering mitochondrial ROS production","confidence":0.8,"supports":true}
{"relationship_key":"RxNorm:495881:treats:MeSH:D000079403","document_id":"PMC12784773_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"A well-known chemotherapeutic agent, sorafenib, has also demonstrated ferroptosis induction.","confidence":0.9,"supports":true}
{"relationship_key":"RxNorm:495881:treats:MeSH:D000079403","document_id":"PMC12784773_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"A well-known chemotherapeutic agent, sorafenib, has also demonstrated ferroptosis induction.","confidence":0.9,"supports":true}
{"relationship_key":"RxNorm:495881:indicates:MeSH:D000079403","document_id":"PMC12784773_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"A well-known chemotherapeutic agent, sorafenib, has also demonstrated ferroptosis induction.","confidence":0.9,"supports":true}
{"relationship_key":"RxNorm:495881:indicates:MeSH:D000079403","document_id":"PMC12784773_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"A well-known chemotherapeutic agent, sorafenib, has also demonstrated ferroptosis induction.","confidence":0.9,"supports":true}
{"relationship_key":"prov:c6bdfd2c6c10498383313a6c2ee38e87:indicates:MeSH:D000079403","document_id":"PMC12784773_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"Although they work through the inhibition of different proteins, both molecules lead to overwhelming oxidative stress and lipid peroxidation and thus, cancer cell death","confidence":0.8,"supports":true}
{"relationship_key":"prov:c6bdfd2c6c10498383313a6c2ee38e87:indicates:MeSH:D000079403","document_id":"PMC12784773_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"Although they work through the inhibition of different proteins, both molecules lead to overwhelming oxidative stress and lipid peroxidation and thus, cancer cell death","confidence":0.8,"supports":true}
{"relationship_key":"prov:1bde9506a0514608bd8d88b9e579a4c5:indicates:MeSH:D000079403","document_id":"PMC12784773_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"Some nanoparticles have been developed that contain erastin or iron analogs, which lead to a selective increase in the intracellular labile iron pool and ROS levels within the tumor cells","confidence":0.8,"supports":true}
{"relationship_key":"prov:1bde9506a0514608bd8d88b9e579a4c5:indicates:MeSH:D000079403","document_id":"PMC12784773_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"Some nanoparticles have been developed that contain erastin or iron analogs, which lead to a selective increase in the intracellular labile iron pool and ROS levels within the tumor cells","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D016923:causes:prov:6c8c3e8198044ae09e3f4e3214a9bc69","document_id":"PMC12784773_window_15","section":null,"start_offset":0,"end_offset":0,"text_span":"demonstrates that metabolic support can preserve redox homeostasis and lipid integrity in nonmalignant mucosal tissue, which suppresses ferroptotic cell death in normal cells following radiation exposure","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D016923:causes:prov:6c8c3e8198044ae09e3f4e3214a9bc69","document_id":"PMC12784773_window_15","section":null,"start_offset":0,"end_offset":0,"text_span":"demonstrates that metabolic support can preserve redox homeostasis and lipid integrity in nonmalignant mucosal tissue, which suppresses ferroptotic cell death in normal cells following radiation exposure","confidence":0.8,"supports":true}
{"relationship_key":"prov:c6bdfd2c6c10498383313a6c2ee38e87:associated_with:MeSH:D000079403","document_id":"PMC12784773_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"These vulnerabilities can be explained, for example, by lowered GPX4 and FSP1 expression in certain immune subsets, making them more susceptible to lipid peroxidation and ferroptosis than malignant cells [37,38].","confidence":0.7,"supports":true}
{"relationship_key":"prov:c6bdfd2c6c10498383313a6c2ee38e87:associated_with:MeSH:D000079403","document_id":"PMC12784773_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"These vulnerabilities can be explained, for example, by lowered GPX4 and FSP1 expression in certain immune subsets, making them more susceptible to lipid peroxidation and ferroptosis than malignant cells [37,38].","confidence":0.7,"supports":true}
{"relationship_key":"prov:c6bdfd2c6c10498383313a6c2ee38e87:associated_with:prov:6c8c3e8198044ae09e3f4e3214a9bc69","document_id":"PMC12784773_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"These vulnerabilities can be explained, for example, by lowered GPX4 and FSP1 expression in certain immune subsets, making them more susceptible to lipid peroxidation and ferroptosis than malignant cells [37,38].","confidence":0.7,"supports":true}
{"relationship_key":"prov:c6bdfd2c6c10498383313a6c2ee38e87:associated_with:prov:6c8c3e8198044ae09e3f4e3214a9bc69","document_id":"PMC12784773_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"These vulnerabilities can be explained, for example, by lowered GPX4 and FSP1 expression in certain immune subsets, making them more susceptible to lipid peroxidation and ferroptosis than malignant cells [37,38].","confidence":0.7,"supports":true}
{"relationship_key":"MeSH:D000079403:increases_risk:MeSH:D016923","document_id":"PMC12784773_window_17","section":null,"start_offset":0,"end_offset":0,"text_span":"As ferroptosis has been shown to influence tumor cell survival both positively and negatively, it also plays an essential role in shaping the tumor microenvironment","confidence":0.7,"supports":true}
{"relationship_key":"MeSH:D000079403:increases_risk:MeSH:D016923","document_id":"PMC12784773_window_17","section":null,"start_offset":0,"end_offset":0,"text_span":"As ferroptosis has been shown to influence tumor cell survival both positively and negatively, it also plays an essential role in shaping the tumor microenvironment","confidence":0.7,"supports":true}
{"relationship_key":"prov:29eae3609135413fa3851640f67e1182:indicates:MeSH:D000079403","document_id":"PMC12784773_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"Metabolic factors such as glutathione depletion, NADPH availability, and intracellular cystine uptake efficiency can also modulate ferroptosis sensitivity","confidence":0.7,"supports":true}
{"relationship_key":"prov:29eae3609135413fa3851640f67e1182:indicates:MeSH:D000079403","document_id":"PMC12784773_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"Metabolic factors such as glutathione depletion, NADPH availability, and intracellular cystine uptake efficiency can also modulate ferroptosis sensitivity","confidence":0.7,"supports":true}
{"relationship_key":"prov:a106c57b758545699035d47110c6d40e:indicates:MeSH:D000079403","document_id":"PMC12784773_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"Metabolic factors such as glutathione depletion, NADPH availability, and intracellular cystine uptake efficiency can also modulate ferroptosis sensitivity","confidence":0.7,"supports":true}
{"relationship_key":"prov:a106c57b758545699035d47110c6d40e:indicates:MeSH:D000079403","document_id":"PMC12784773_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"Metabolic factors such as glutathione depletion, NADPH availability, and intracellular cystine uptake efficiency can also modulate ferroptosis sensitivity","confidence":0.7,"supports":true}
{"relationship_key":"prov:48384bb525f04fd58d6e7c79dab1b8cd:indicates:MeSH:D000079403","document_id":"PMC12784773_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"Metabolic factors such as glutathione depletion, NADPH availability, and intracellular cystine uptake efficiency can also modulate ferroptosis sensitivity","confidence":0.7,"supports":true}
{"relationship_key":"prov:48384bb525f04fd58d6e7c79dab1b8cd:indicates:MeSH:D000079403","document_id":"PMC12784773_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"Metabolic factors such as glutathione depletion, NADPH availability, and intracellular cystine uptake efficiency can also modulate ferroptosis sensitivity","confidence":0.7,"supports":true}
{"relationship_key":"prov:e6422b10d8fb438b9eade8b91f498d7f:treats:MeSH:D000079403","document_id":"PMC12784773_window_22","section":null,"start_offset":0,"end_offset":0,"text_span":"Small molecules such as erastin, RSL3, and sorafenib can induce ferroptosis in malignant cells,","confidence":0.8,"supports":true}
{"relationship_key":"prov:e6422b10d8fb438b9eade8b91f498d7f:treats:MeSH:D000079403","document_id":"PMC12784773_window_22","section":null,"start_offset":0,"end_offset":0,"text_span":"Small molecules such as erastin, RSL3, and sorafenib can induce ferroptosis in malignant cells,","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D057765:affects:MeSH:D001249","document_id":"PMC12788344_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"She had a history of controlled eosinophilic esophagitis, asthma,","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D057765:affects:MeSH:D001249","document_id":"PMC12788344_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"She had a history of controlled eosinophilic esophagitis, asthma,","confidence":0.8,"supports":true}
{"relationship_key":"prov:9aba2d3e74f44c2eb4d1539eae4da778:affects:prov:2e41139abdb94579af5a8ce6d49353a0","document_id":"PMC12788344_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Mammography demonstrated extremely dense breast tissue with new calcifications in both breasts.","confidence":0.9,"supports":true}
{"relationship_key":"prov:9aba2d3e74f44c2eb4d1539eae4da778:affects:prov:2e41139abdb94579af5a8ce6d49353a0","document_id":"PMC12788344_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"Mammography demonstrated extremely dense breast tissue with new calcifications in both breasts.","confidence":0.9,"supports":true}
{"relationship_key":"prov:953f0e810ee942228943497f269a2fd4:diagnosed_by:MeSH:D003113","document_id":"PMC12788344_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"She subsequently underwent stereotactic needle biopsies of both areas,","confidence":0.7,"supports":true}
{"relationship_key":"prov:953f0e810ee942228943497f269a2fd4:diagnosed_by:MeSH:D003113","document_id":"PMC12788344_window_0","section":null,"start_offset":0,"end_offset":0,"text_span":"She subsequently underwent stereotactic needle biopsies of both areas,","confidence":0.7,"supports":true}
{"relationship_key":"prov:953f0e810ee942228943497f269a2fd4:diagnosed_by:prov:c813a2bb51c24744823cfc3e6b30328c","document_id":"PMC12788344_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"which revealed right breast ductal carcinoma in situ (DCIS), nuclear grade 3,","confidence":0.9,"supports":true}
{"relationship_key":"prov:953f0e810ee942228943497f269a2fd4:diagnosed_by:prov:c813a2bb51c24744823cfc3e6b30328c","document_id":"PMC12788344_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"which revealed right breast ductal carcinoma in situ (DCIS), nuclear grade 3,","confidence":0.9,"supports":true}
{"relationship_key":"prov:953f0e810ee942228943497f269a2fd4:indicates:prov:2e21cdadaceb4428bd7012ed2b07b459","document_id":"PMC12788344_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"Within the left breast biopsy there was an absence of myoepithelial cells, raising concern that the findings reflected an unusual type of invasive carcinoma.","confidence":0.8,"supports":true}
{"relationship_key":"prov:953f0e810ee942228943497f269a2fd4:indicates:prov:2e21cdadaceb4428bd7012ed2b07b459","document_id":"PMC12788344_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"Within the left breast biopsy there was an absence of myoepithelial cells, raising concern that the findings reflected an unusual type of invasive carcinoma.","confidence":0.8,"supports":true}
{"relationship_key":"prov:e4921a960ea644e387920e2248d26ed5:indicates:prov:dab73692a911422796f8dd99a64a3dd6","document_id":"PMC12788344_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"A biopsy of the mass demonstrated a spindle cell tumor, favoring malignant phyllodes tumor with pleomorphic liposarcomatous differentiation","confidence":0.8,"supports":true}
{"relationship_key":"prov:e4921a960ea644e387920e2248d26ed5:indicates:prov:dab73692a911422796f8dd99a64a3dd6","document_id":"PMC12788344_window_1","section":null,"start_offset":0,"end_offset":0,"text_span":"A biopsy of the mass demonstrated a spindle cell tumor, favoring malignant phyllodes tumor with pleomorphic liposarcomatous differentiation","confidence":0.8,"supports":true}
{"relationship_key":"prov:e4921a960ea644e387920e2248d26ed5:diagnosed_by:prov:639c97c27029445498a5a47f6a433bb6","document_id":"PMC12788344_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"Bilateral mastectomies were performed, and 22 mm of DCIS was found in the right breast,","confidence":0.8,"supports":true}
{"relationship_key":"prov:e4921a960ea644e387920e2248d26ed5:diagnosed_by:prov:639c97c27029445498a5a47f6a433bb6","document_id":"PMC12788344_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"Bilateral mastectomies were performed, and 22 mm of DCIS was found in the right breast,","confidence":0.8,"supports":true}
{"relationship_key":"prov:e4921a960ea644e387920e2248d26ed5:diagnosed_by:MeSH:D008408","document_id":"PMC12788344_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"Bilateral mastectomies were performed,","confidence":0.8,"supports":true}
{"relationship_key":"prov:e4921a960ea644e387920e2248d26ed5:diagnosed_by:MeSH:D008408","document_id":"PMC12788344_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"Bilateral mastectomies were performed,","confidence":0.8,"supports":true}
{"relationship_key":"prov:67a6e2e9c40947a88af7dce3951fefca:indicates:prov:e4921a960ea644e387920e2248d26ed5","document_id":"PMC12788344_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"A separate biopsy of a left breast mass revealed a malignant fibroepithelial lesion containing a benign epithelial component and a high‐grade malignant spindle cell component with lipoblastic differentiation.","confidence":0.9,"supports":true}
{"relationship_key":"prov:67a6e2e9c40947a88af7dce3951fefca:indicates:prov:e4921a960ea644e387920e2248d26ed5","document_id":"PMC12788344_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"A separate biopsy of a left breast mass revealed a malignant fibroepithelial lesion containing a benign epithelial component and a high‐grade malignant spindle cell component with lipoblastic differentiation.","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:A0A224YDC9:indicates:prov:e4921a960ea644e387920e2248d26ed5","document_id":"PMC12788344_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"The spindle cell component was negative for numerous cytokeratin stains and p63.","confidence":0.9,"supports":true}
{"relationship_key":"UniProt:A0A224YDC9:indicates:prov:e4921a960ea644e387920e2248d26ed5","document_id":"PMC12788344_window_3","section":null,"start_offset":0,"end_offset":0,"text_span":"The spindle cell component was negative for numerous cytokeratin stains and p63.","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Dense_breast_tissue:associated_with:prov:2e41139abdb94579af5a8ce6d49353a0","document_id":"PMC12788344_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"Her mammogram showed new calcifications in both breasts (Figure 4) and dense breast tissue, which limits the sensitivity of mammography.","confidence":1.0,"supports":true}
{"relationship_key":"DBPedia:Dense_breast_tissue:associated_with:prov:2e41139abdb94579af5a8ce6d49353a0","document_id":"PMC12788344_window_6","section":null,"start_offset":0,"end_offset":0,"text_span":"Her mammogram showed new calcifications in both breasts (Figure 4) and dense breast tissue, which limits the sensitivity of mammography.","confidence":1.0,"supports":true}
{"relationship_key":"prov:2217d6fd5e364413aba546334604ffe9:indicates:MeSH:D000082182","document_id":"PMC12788344_window_9","section":null,"start_offset":0,"end_offset":0,"text_span":"corresponding to circulating tumor DNA that can be observed in individuals with metastatic cancers","confidence":0.7,"supports":true}
{"relationship_key":"prov:2217d6fd5e364413aba546334604ffe9:indicates:MeSH:D000082182","document_id":"PMC12788344_window_9","section":null,"start_offset":0,"end_offset":0,"text_span":"corresponding to circulating tumor DNA that can be observed in individuals with metastatic cancers","confidence":0.7,"supports":true}
{"relationship_key":"prov:9e3561d19b35465191fa23e857d35a70:diagnosed_by:MeSH:D008408","document_id":"PMC12788344_window_9","section":null,"start_offset":0,"end_offset":0,"text_span":"An LFS diagnosis in an individual with newly diagnosed breast cancer includes consideration of bilateral mastectomy","confidence":0.6,"supports":true}
{"relationship_key":"prov:9e3561d19b35465191fa23e857d35a70:diagnosed_by:MeSH:D008408","document_id":"PMC12788344_window_9","section":null,"start_offset":0,"end_offset":0,"text_span":"An LFS diagnosis in an individual with newly diagnosed breast cancer includes consideration of bilateral mastectomy","confidence":0.6,"supports":true}
{"relationship_key":"prov:9510cdf77a854a7cbf2f06886d2a7f9e:treats:prov:9e3561d19b35465191fa23e857d35a70","document_id":"PMC12788344_window_9","section":null,"start_offset":0,"end_offset":0,"text_span":"Germline genetic testing, typically in the form of multigene panels using next‐generation sequencing","confidence":0.4,"supports":true}
{"relationship_key":"prov:9510cdf77a854a7cbf2f06886d2a7f9e:treats:prov:9e3561d19b35465191fa23e857d35a70","document_id":"PMC12788344_window_9","section":null,"start_offset":0,"end_offset":0,"text_span":"Germline genetic testing, typically in the form of multigene panels using next‐generation sequencing","confidence":0.4,"supports":true}
{"relationship_key":"MeSH:D000082182:diagnosed_by:prov:7cc4d9965b3a41e4a539238d3d724dde","document_id":"PMC12788344_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"Immunohistochemistry was performed on cell blocks.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D000082182:diagnosed_by:prov:7cc4d9965b3a41e4a539238d3d724dde","document_id":"PMC12788344_window_10","section":null,"start_offset":0,"end_offset":0,"text_span":"Immunohistochemistry was performed on cell blocks.","confidence":0.9,"supports":true}
{"relationship_key":"prov:f80f52b5faa543c0804a65405346fa0c:diagnosed_by:prov:7cc4d9965b3a41e4a539238d3d724dde","document_id":"PMC12788344_window_11","section":null,"start_offset":0,"end_offset":0,"text_span":"Typically, in a clinical genetics practice, if an individual is has a de novo disease-causing variant identified (for example, in an autosomal-dominant condition), part of the counseling around this PV/LPV is that there is a slightly increased recurrence risk (typically 1%–5% recurrence risk in future pregnancies) because of the risk for gonadal mosaicism,","confidence":0.9,"supports":true}
{"relationship_key":"prov:f80f52b5faa543c0804a65405346fa0c:diagnosed_by:prov:7cc4d9965b3a41e4a539238d3d724dde","document_id":"PMC12788344_window_11","section":null,"start_offset":0,"end_offset":0,"text_span":"Typically, in a clinical genetics practice, if an individual is has a de novo disease-causing variant identified (for example, in an autosomal-dominant condition), part of the counseling around this PV/LPV is that there is a slightly increased recurrence risk (typically 1%–5% recurrence risk in future pregnancies) because of the risk for gonadal mosaicism,","confidence":0.9,"supports":true}
{"relationship_key":"prov:f80f52b5faa543c0804a65405346fa0c:associated_with:prov:7cc4d9965b3a41e4a539238d3d724dde","document_id":"PMC12788344_window_11","section":null,"start_offset":0,"end_offset":0,"text_span":"Other examples include PIK3CA-related overgrowth syndromes (which can result in focal or segmental overgrowth) or mosaic Turner syndrome,","confidence":0.8,"supports":true}
{"relationship_key":"prov:f80f52b5faa543c0804a65405346fa0c:associated_with:prov:7cc4d9965b3a41e4a539238d3d724dde","document_id":"PMC12788344_window_11","section":null,"start_offset":0,"end_offset":0,"text_span":"Other examples include PIK3CA-related overgrowth syndromes (which can result in focal or segmental overgrowth) or mosaic Turner syndrome,","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D000082182:increases_risk:MeSH:D015470","document_id":"PMC12788344_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"CHIP is the result of expansion of mutant hematopoietic stem and progenitor cells and is associated with increased risk for hematologic neoplasm (such as myelodysplastic syndromes and acute myeloid leukemia).","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D000082182:increases_risk:MeSH:D015470","document_id":"PMC12788344_window_12","section":null,"start_offset":0,"end_offset":0,"text_span":"CHIP is the result of expansion of mutant hematopoietic stem and progenitor cells and is associated with increased risk for hematologic neoplasm (such as myelodysplastic syndromes and acute myeloid leukemia).","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D000082182:diagnosed_by:MeSH:D007157","document_id":"PMC12788344_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"Whole‐body MRI scan was recommended per NCCN guidelines given the possibility of other primary cancers in a patient with concern for LFS.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D000082182:diagnosed_by:MeSH:D007157","document_id":"PMC12788344_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"Whole‐body MRI scan was recommended per NCCN guidelines given the possibility of other primary cancers in a patient with concern for LFS.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D000082182:associated_with:prov:0e96e1e717b24fafbadf1e256beae221","document_id":"PMC12788344_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"It provides an opportunity to consider reproductive options, such as in vitro fertilization with preimplantation genetic diagnosis.","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D000082182:associated_with:prov:0e96e1e717b24fafbadf1e256beae221","document_id":"PMC12788344_window_14","section":null,"start_offset":0,"end_offset":0,"text_span":"It provides an opportunity to consider reproductive options, such as in vitro fertilization with preimplantation genetic diagnosis.","confidence":0.8,"supports":true}
{"relationship_key":"MeSH:D007889:diagnosed_by:prov:6a2c3475698048509b770f1183dcc4a3","document_id":"PMC12788344_window_15","section":null,"start_offset":0,"end_offset":0,"text_span":"Pelvic ultrasound showed an anterior fundal pedunculated fibroid measuring 5.5 × 3.4 × 4.5 cm and a second posterior fundal fibroid measuring 2.6 × 2.6 × 2.6 cm.","confidence":0.0,"supports":true}
{"relationship_key":"MeSH:D007889:diagnosed_by:prov:6a2c3475698048509b770f1183dcc4a3","document_id":"PMC12788344_window_15","section":null,"start_offset":0,"end_offset":0,"text_span":"Pelvic ultrasound showed an anterior fundal pedunculated fibroid measuring 5.5 × 3.4 × 4.5 cm and a second posterior fundal fibroid measuring 2.6 × 2.6 × 2.6 cm.","confidence":0.0,"supports":true}
{"relationship_key":"prov:f7a0b95e962b499a9c54fcb56201374c:diagnosed_by:prov:db7273c9f658439ea003134c8b481bd0","document_id":"PMC12788344_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"Notable extra data for this patient were available because she was concurrently going through the process of in vitro fertilization and preimplantation genetic diagnosis.","confidence":0.8,"supports":true}
{"relationship_key":"prov:f7a0b95e962b499a9c54fcb56201374c:diagnosed_by:prov:db7273c9f658439ea003134c8b481bd0","document_id":"PMC12788344_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"Notable extra data for this patient were available because she was concurrently going through the process of in vitro fertilization and preimplantation genetic diagnosis.","confidence":0.8,"supports":true}
{"relationship_key":"prov:f7a0b95e962b499a9c54fcb56201374c:diagnosed_by:prov:495e61bcdd3442c4adb3d71ff0be8240","document_id":"PMC12788344_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"Notable extra data for this patient were available because she was concurrently going through the process of in vitro fertilization and preimplantation genetic diagnosis.","confidence":0.8,"supports":true}
{"relationship_key":"prov:f7a0b95e962b499a9c54fcb56201374c:diagnosed_by:prov:495e61bcdd3442c4adb3d71ff0be8240","document_id":"PMC12788344_window_16","section":null,"start_offset":0,"end_offset":0,"text_span":"Notable extra data for this patient were available because she was concurrently going through the process of in vitro fertilization and preimplantation genetic diagnosis.","confidence":0.8,"supports":true}
{"relationship_key":"prov:0e96e1e717b24fafbadf1e256beae221:associated_with:prov:7cc4d9965b3a41e4a539238d3d724dde","document_id":"PMC12788344_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"The evidence of the somatic molecular testing and the embryos is consistent with mosaicism in our patient","confidence":1.0,"supports":true}
{"relationship_key":"prov:0e96e1e717b24fafbadf1e256beae221:associated_with:prov:7cc4d9965b3a41e4a539238d3d724dde","document_id":"PMC12788344_window_19","section":null,"start_offset":0,"end_offset":0,"text_span":"The evidence of the somatic molecular testing and the embryos is consistent with mosaicism in our patient","confidence":1.0,"supports":true}
{"relationship_key":"prov:e7542271820d47988fcf3afac0d1f79a:located_in:prov:67708627ab9a4ef9a87ad38f1bde8e98","document_id":"PMC12788344_window_22","section":null,"start_offset":0,"end_offset":0,"text_span":"The sensory nerves to the nipple course through the breast parenchyma and are transected during mastectomy,","confidence":0.6,"supports":true}
{"relationship_key":"prov:e7542271820d47988fcf3afac0d1f79a:located_in:prov:67708627ab9a4ef9a87ad38f1bde8e98","document_id":"PMC12788344_window_22","section":null,"start_offset":0,"end_offset":0,"text_span":"The sensory nerves to the nipple course through the breast parenchyma and are transected during mastectomy,","confidence":0.6,"supports":true}
{"relationship_key":"prov:d14cf21986d146988becb85f367fc214:diagnosed_by:prov:17ffa3e1eabe49ccac79bb6b585bc8bc","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"The role of neurotization is to restore this function as well as to minimize chronic pain in the reconstructed breast,","confidence":0.9,"supports":true}
{"relationship_key":"prov:d14cf21986d146988becb85f367fc214:diagnosed_by:prov:17ffa3e1eabe49ccac79bb6b585bc8bc","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"The role of neurotization is to restore this function as well as to minimize chronic pain in the reconstructed breast,","confidence":0.9,"supports":true}
{"relationship_key":"prov:17ffa3e1eabe49ccac79bb6b585bc8bc:manages:prov:d14cf21986d146988becb85f367fc214","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"The role of neurotization is to restore this function as well as to minimize chronic pain in the reconstructed breast,","confidence":0.9,"supports":true}
{"relationship_key":"prov:17ffa3e1eabe49ccac79bb6b585bc8bc:manages:prov:d14cf21986d146988becb85f367fc214","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"The role of neurotization is to restore this function as well as to minimize chronic pain in the reconstructed breast,","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D002637:affects:prov:d14cf21986d146988becb85f367fc214","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"The role of neurotization is to restore this function as well as to minimize chronic pain in the reconstructed breast,","confidence":0.6,"supports":true}
{"relationship_key":"MeSH:D002637:affects:prov:d14cf21986d146988becb85f367fc214","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"The role of neurotization is to restore this function as well as to minimize chronic pain in the reconstructed breast,","confidence":0.6,"supports":true}
{"relationship_key":"MeSH:D002637:affects:prov:e7542271820d47988fcf3afac0d1f79a","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"The sensory nerves to the nipple course through the breast parenchyma and are transected during mastectomy,","confidence":0.6,"supports":true}
{"relationship_key":"MeSH:D002637:affects:prov:e7542271820d47988fcf3afac0d1f79a","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"The sensory nerves to the nipple course through the breast parenchyma and are transected during mastectomy,","confidence":0.6,"supports":true}
{"relationship_key":"prov:8512ec04fd1f429bb88a39ad443aea8a:indicates:prov:d14cf21986d146988becb85f367fc214","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"The sensory nerves to the nipple course through the breast parenchyma and are transected during mastectomy,","confidence":0.5,"supports":true}
{"relationship_key":"prov:8512ec04fd1f429bb88a39ad443aea8a:indicates:prov:d14cf21986d146988becb85f367fc214","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"The sensory nerves to the nipple course through the breast parenchyma and are transected during mastectomy,","confidence":0.5,"supports":true}
{"relationship_key":"prov:8512ec04fd1f429bb88a39ad443aea8a:indicates:prov:e7542271820d47988fcf3afac0d1f79a","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"The sensory nerves to the nipple course through the breast parenchyma and are transected during mastectomy,","confidence":0.5,"supports":true}
{"relationship_key":"prov:8512ec04fd1f429bb88a39ad443aea8a:indicates:prov:e7542271820d47988fcf3afac0d1f79a","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"The sensory nerves to the nipple course through the breast parenchyma and are transected during mastectomy,","confidence":0.5,"supports":true}
{"relationship_key":"prov:d14cf21986d146988becb85f367fc214:associated_with:prov:87f79459008d4d6da6c3c6d900aecd73","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"A meta‐analysis by Smeele et al. identified the anterior cutaneous branch and lateral cutaneous branch of the fourth intercostal nerve as suppliers of the largest surface area of the breast skin and nipple/nipple–areola complex.","confidence":0.4,"supports":true}
{"relationship_key":"prov:d14cf21986d146988becb85f367fc214:associated_with:prov:87f79459008d4d6da6c3c6d900aecd73","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"A meta‐analysis by Smeele et al. identified the anterior cutaneous branch and lateral cutaneous branch of the fourth intercostal nerve as suppliers of the largest surface area of the breast skin and nipple/nipple–areola complex.","confidence":0.4,"supports":true}
{"relationship_key":"prov:d14cf21986d146988becb85f367fc214:associated_with:prov:9e53bfc83b964b2aa869fa248e875470","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"A meta‐analysis by Smeele et al. identified the anterior cutaneous branch and lateral cutaneous branch of the fourth intercostal nerve as suppliers of the largest surface area of the breast skin and nipple/nipple–areola complex.","confidence":0.4,"supports":true}
{"relationship_key":"prov:d14cf21986d146988becb85f367fc214:associated_with:prov:9e53bfc83b964b2aa869fa248e875470","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"A meta‐analysis by Smeele et al. identified the anterior cutaneous branch and lateral cutaneous branch of the fourth intercostal nerve as suppliers of the largest surface area of the breast skin and nipple/nipple–areola complex.","confidence":0.4,"supports":true}
{"relationship_key":"prov:e7542271820d47988fcf3afac0d1f79a:associated_with:prov:87f79459008d4d6da6c3c6d900aecd73","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"A meta‐analysis by Smeele et al. identified the anterior cutaneous branch and lateral cutaneous branch of the fourth intercostal nerve as suppliers of the largest surface area of the breast skin and nipple/nipple–areola complex.","confidence":0.4,"supports":true}
{"relationship_key":"prov:e7542271820d47988fcf3afac0d1f79a:associated_with:prov:87f79459008d4d6da6c3c6d900aecd73","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"A meta‐analysis by Smeele et al. identified the anterior cutaneous branch and lateral cutaneous branch of the fourth intercostal nerve as suppliers of the largest surface area of the breast skin and nipple/nipple–areola complex.","confidence":0.4,"supports":true}
{"relationship_key":"prov:e7542271820d47988fcf3afac0d1f79a:associated_with:prov:9e53bfc83b964b2aa869fa248e875470","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"A meta‐analysis by Smeele et al. identified the anterior cutaneous branch and lateral cutaneous branch of the fourth intercostal nerve as suppliers of the largest surface area of the breast skin and nipple/nipple–areola complex.","confidence":0.4,"supports":true}
{"relationship_key":"prov:e7542271820d47988fcf3afac0d1f79a:associated_with:prov:9e53bfc83b964b2aa869fa248e875470","document_id":"PMC12788344_window_23","section":null,"start_offset":0,"end_offset":0,"text_span":"A meta‐analysis by Smeele et al. identified the anterior cutaneous branch and lateral cutaneous branch of the fourth intercostal nerve as suppliers of the largest surface area of the breast skin and nipple/nipple–areola complex.","confidence":0.4,"supports":true}
{"relationship_key":"prov:8512ec04fd1f429bb88a39ad443aea8a:affects:prov:e7542271820d47988fcf3afac0d1f79a","document_id":"PMC12788344_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"but Djohan et al. demonstrated improvements in skin and nipple sensation, but with decreased sensation compared with preoperative testing","confidence":0.9,"supports":true}
{"relationship_key":"prov:8512ec04fd1f429bb88a39ad443aea8a:affects:prov:e7542271820d47988fcf3afac0d1f79a","document_id":"PMC12788344_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"but Djohan et al. demonstrated improvements in skin and nipple sensation, but with decreased sensation compared with preoperative testing","confidence":0.9,"supports":true}
{"relationship_key":"prov:8512ec04fd1f429bb88a39ad443aea8a:affects:prov:d14cf21986d146988becb85f367fc214","document_id":"PMC12788344_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"but Djohan et al. demonstrated improvements in skin and nipple sensation, but with decreased sensation compared with preoperative testing","confidence":0.9,"supports":true}
{"relationship_key":"prov:8512ec04fd1f429bb88a39ad443aea8a:affects:prov:d14cf21986d146988becb85f367fc214","document_id":"PMC12788344_window_24","section":null,"start_offset":0,"end_offset":0,"text_span":"but Djohan et al. demonstrated improvements in skin and nipple sensation, but with decreased sensation compared with preoperative testing","confidence":0.9,"supports":true}
{"relationship_key":"prov:302221c16069425b9f33bbb6280e8111:associated_with:prov:67708627ab9a4ef9a87ad38f1bde8e98","document_id":"PMC12788344_window_28","section":null,"start_offset":0,"end_offset":0,"text_span":"In this procedure, SPIO is injected into the breast parenchyma at the time of the primary breast surgery for DCIS","confidence":0.6,"supports":true}
{"relationship_key":"prov:302221c16069425b9f33bbb6280e8111:associated_with:prov:67708627ab9a4ef9a87ad38f1bde8e98","document_id":"PMC12788344_window_28","section":null,"start_offset":0,"end_offset":0,"text_span":"In this procedure, SPIO is injected into the breast parenchyma at the time of the primary breast surgery for DCIS","confidence":0.6,"supports":true}
{"relationship_key":"MeSH:D008408:manages:prov:5618d9a5c13d4684b7af6d2f5db1be82","document_id":"PMC12788344_window_28","section":null,"start_offset":0,"end_offset":0,"text_span":"The SentiNot trial included patients with DCIS undergoing mastectomy, with DCIS grade 2 measuring >2 cm, with any size grade 3 DCIS, or with any mass‐forming DCIS","confidence":0.5,"supports":true}
{"relationship_key":"MeSH:D008408:manages:prov:5618d9a5c13d4684b7af6d2f5db1be82","document_id":"PMC12788344_window_28","section":null,"start_offset":0,"end_offset":0,"text_span":"The SentiNot trial included patients with DCIS undergoing mastectomy, with DCIS grade 2 measuring >2 cm, with any size grade 3 DCIS, or with any mass‐forming DCIS","confidence":0.5,"supports":true}
{"relationship_key":"MeSH:D008408:manages:prov:302221c16069425b9f33bbb6280e8111","document_id":"PMC12788344_window_28","section":null,"start_offset":0,"end_offset":0,"text_span":"The SentiNot trial included patients with DCIS undergoing mastectomy, with DCIS grade 2 measuring >2 cm, with any size grade 3 DCIS, or with any mass‐forming DCIS","confidence":0.5,"supports":true}
{"relationship_key":"MeSH:D008408:manages:prov:302221c16069425b9f33bbb6280e8111","document_id":"PMC12788344_window_28","section":null,"start_offset":0,"end_offset":0,"text_span":"The SentiNot trial included patients with DCIS undergoing mastectomy, with DCIS grade 2 measuring >2 cm, with any size grade 3 DCIS, or with any mass‐forming DCIS","confidence":0.5,"supports":true}
{"relationship_key":"prov:3cd7abccbbb9465996e2aad9039b1571:treats:prov:5618d9a5c13d4684b7af6d2f5db1be82","document_id":"PMC12788344_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"If surgery is pursued, adjuvant therapy for DCIS typically involves radiation and/or hormone therapy.","confidence":0.9,"supports":true}
{"relationship_key":"prov:3cd7abccbbb9465996e2aad9039b1571:treats:prov:5618d9a5c13d4684b7af6d2f5db1be82","document_id":"PMC12788344_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"If surgery is pursued, adjuvant therapy for DCIS typically involves radiation and/or hormone therapy.","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Hormone_replacement_therapy:treats:prov:5618d9a5c13d4684b7af6d2f5db1be82","document_id":"PMC12788344_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"If surgery is pursued, adjuvant therapy for DCIS typically involves radiation and/or hormone therapy.","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Hormone_replacement_therapy:treats:prov:5618d9a5c13d4684b7af6d2f5db1be82","document_id":"PMC12788344_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"If surgery is pursued, adjuvant therapy for DCIS typically involves radiation and/or hormone therapy.","confidence":0.9,"supports":true}
{"relationship_key":"prov:5618d9a5c13d4684b7af6d2f5db1be82:diagnosed_by:DBPedia:Lumpectomy","document_id":"PMC12788344_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"breast‐conserving surgery for DCIS is typically offered as initial management.","confidence":0.8,"supports":true}
{"relationship_key":"prov:5618d9a5c13d4684b7af6d2f5db1be82:diagnosed_by:DBPedia:Lumpectomy","document_id":"PMC12788344_window_29","section":null,"start_offset":0,"end_offset":0,"text_span":"breast‐conserving surgery for DCIS is typically offered as initial management.","confidence":0.8,"supports":true}
{"relationship_key":"prov:7e11a6202d8846dc9327b1151c36a95a:treats:prov:70a31d58976f4394b3b2575d1f144ed0","document_id":"PMC12788344_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"adjuvant hormone therapy with the use of selective ER modulators and aromatase inhibitors plays a role in chemoprevention for both invasive breast cancer and DCIS","confidence":0.9,"supports":true}
{"relationship_key":"prov:7e11a6202d8846dc9327b1151c36a95a:treats:prov:70a31d58976f4394b3b2575d1f144ed0","document_id":"PMC12788344_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"adjuvant hormone therapy with the use of selective ER modulators and aromatase inhibitors plays a role in chemoprevention for both invasive breast cancer and DCIS","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Aromatase_inhibitor:treats:prov:70a31d58976f4394b3b2575d1f144ed0","document_id":"PMC12788344_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"adjuvant hormone therapy with the use of selective ER modulators and aromatase inhibitors plays a role in chemoprevention for both invasive breast cancer and DCIS","confidence":0.9,"supports":true}
{"relationship_key":"DBPedia:Aromatase_inhibitor:treats:prov:70a31d58976f4394b3b2575d1f144ed0","document_id":"PMC12788344_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"adjuvant hormone therapy with the use of selective ER modulators and aromatase inhibitors plays a role in chemoprevention for both invasive breast cancer and DCIS","confidence":0.9,"supports":true}
{"relationship_key":"RxNorm:10324:treats:prov:70a31d58976f4394b3b2575d1f144ed0","document_id":"PMC12788344_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"The NSABP B‐24 trial investigated adjuvant treatment with tamoxifen for 5 years","confidence":0.9,"supports":true}
{"relationship_key":"RxNorm:10324:treats:prov:70a31d58976f4394b3b2575d1f144ed0","document_id":"PMC12788344_window_32","section":null,"start_offset":0,"end_offset":0,"text_span":"The NSABP B‐24 trial investigated adjuvant treatment with tamoxifen for 5 years","confidence":0.9,"supports":true}
{"relationship_key":"prov:e4921a960ea644e387920e2248d26ed5:diagnosed_by:DBPedia:Lumpectomy","document_id":"PMC12788344_window_33","section":null,"start_offset":0,"end_offset":0,"text_span":"Local excision or lumpectomy is acceptable for benign phyllodes tumors.","confidence":0.8,"supports":true}
{"relationship_key":"prov:e4921a960ea644e387920e2248d26ed5:diagnosed_by:DBPedia:Lumpectomy","document_id":"PMC12788344_window_33","section":null,"start_offset":0,"end_offset":0,"text_span":"Local excision or lumpectomy is acceptable for benign phyllodes tumors.","confidence":0.8,"supports":true}
{"relationship_key":"prov:3cd7abccbbb9465996e2aad9039b1571:treats:prov:e4921a960ea644e387920e2248d26ed5","document_id":"PMC12788344_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"Mastectomy reduces the risk of local recurrence and improves disease free survival for borderline and malignant phyllodes tumors, although wide local excision with negative margins is also an acceptable approach.","confidence":0.8,"supports":true}
{"relationship_key":"prov:3cd7abccbbb9465996e2aad9039b1571:treats:prov:e4921a960ea644e387920e2248d26ed5","document_id":"PMC12788344_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"Mastectomy reduces the risk of local recurrence and improves disease free survival for borderline and malignant phyllodes tumors, although wide local excision with negative margins is also an acceptable approach.","confidence":0.8,"supports":true}
{"relationship_key":"prov:e4921a960ea644e387920e2248d26ed5:diagnosed_by:prov:954e448f7f7e4232982c9e47b1758963","document_id":"PMC12788344_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"Phyllodes tumors have been associated with germline TP53, BRCA1, and RB1 PVs/LPVs.","confidence":0.9,"supports":true}
{"relationship_key":"prov:e4921a960ea644e387920e2248d26ed5:diagnosed_by:prov:954e448f7f7e4232982c9e47b1758963","document_id":"PMC12788344_window_34","section":null,"start_offset":0,"end_offset":0,"text_span":"Phyllodes tumors have been associated with germline TP53, BRCA1, and RB1 PVs/LPVs.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D007938:diagnoses:DBPedia:Complete_blood_count","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3–4 months to screen for leukemia and lymphoma.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D007938:diagnoses:DBPedia:Complete_blood_count","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3–4 months to screen for leukemia and lymphoma.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D007938:diagnoses:prov:5bc063b4f83a437ba10d996e2902a72b","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3–4 months to screen for leukemia and lymphoma.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D007938:diagnoses:prov:5bc063b4f83a437ba10d996e2902a72b","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3–4 months to screen for leukemia and lymphoma.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D007938:diagnoses:DBPedia:Lactate_dehydrogenase","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3–4 months to screen for leukemia and lymphoma.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D007938:diagnoses:DBPedia:Lactate_dehydrogenase","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3–4 months to screen for leukemia and lymphoma.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D008223:diagnoses:DBPedia:Complete_blood_count","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3–4 months to screen for leukemia and lymphoma.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D008223:diagnoses:DBPedia:Complete_blood_count","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3–4 months to screen for leukemia and lymphoma.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D008223:diagnoses:prov:5bc063b4f83a437ba10d996e2902a72b","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3–4 months to screen for leukemia and lymphoma.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D008223:diagnoses:prov:5bc063b4f83a437ba10d996e2902a72b","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3–4 months to screen for leukemia and lymphoma.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D008223:diagnoses:DBPedia:Lactate_dehydrogenase","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3–4 months to screen for leukemia and lymphoma.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D008223:diagnoses:DBPedia:Lactate_dehydrogenase","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3–4 months to screen for leukemia and lymphoma.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D018268:diagnoses:MeSH:D007157","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Adrenocortical carcinoma surveillance should continue until at least age 40 years.","confidence":0.9,"supports":true}
{"relationship_key":"MeSH:D018268:diagnoses:MeSH:D007157","document_id":"PMC12788344_window_37","section":null,"start_offset":0,"end_offset":0,"text_span":"Adrenocortical carcinoma surveillance should continue until at least age 40 years.","confidence":0.9,"supports":true}
